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ABSTRACT 
 
Optical imaging of biomolecules and chemicals has been instrumental in detecting 
the target of interest for many diverse fields such as biomedicine, nanotechnology, and 
chemical science. With the recent advances of optical measurement for reflection, 
absorbance, and fluorescence, highly sensitive analysis to confirm the presence of specific 
biomolecules that cause diseases and of individual chemicals is achieved. However, 
conventional imaging methods depend on expensive laboratory-based instruments, and 
there is an increasing need for advanced sensing techniques that can be conducted 
regardless of space and time to facilitate the scenario of point-of-care diagnostics (POCD).  
To meet the needs, affordable and portable sensing systems are developed using a 
smartphone. Incorporation of bio/chemical sensing technology into mobile platforms is a 
potentially powerful development, as assay capabilities that have previously only been 
available through laboratory instruments may be utilized by anyone. Such developments 
can help to achieve the goal of POCD in which out-of-laboratory tests may be used for 
molecular analysis and chemical detection. The systems integrated with a smartphone may 
also enable diagnostic technology that can be translated to resource-poor regions of the 
world. The systems, deployed widely, would be capable of rapidly testing suspected 
chemicals, or tracking the development of a medical condition throughout a large 
population. 
The development of novel sensing systems is completed with two separate goals. 
One is loop-mediated isothermal amplification based disease detection, and the other is 
thin layer chromatography based counterfeit medication analysis. In the biosensing 
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approach, not only do the system detect viruses like zika, dengue, and chikungunya that 
cause human infectious diseases, but it diagnoses equine pathogens such as Streptococcus 
Zooepidemicus, Streptococcus Equi, and equine herpesviruses. Three different 
medications—paracetamol, nevirapine, and amodiaquine—are tested, and the counterfeit 
is distinguished from the genuine in chemical analysis. The systems consist of a 
smartphone with a customized application software, a cradle that supports internal 
electromechanical devices, and a microfluidic chip/plate where the assay occurs. Assay 
results from the inexpensive and handheld sensor instrument are comparable to those from 
conventional laboratory equipment, and the demonstration shows the potential utility of 
the newly developed system for the applications of POCD. 
The ideal highly sensitive, inexpensive, and portable sensor is achieved using a 
mobile phone for bio/chemical applications. The exceptional computational and imaging 
capabilities of current smartphones enable their use as a convenient platform to perform 
assays and minimize cost and system complexity. The system could open a new era of fast, 
affordable, and accurate biomolecular and chemical diagnosis. With further customization 
specific to the diseases and medications, it would be utilized as a promising diagnostic tool 
to accomplish the POCD in low-income and resource-limited regions. 
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CHAPTER 1 
CHARACTERIZATION OF DRUG AUTHENTICITY USING         
THIN LAYER CHROMATOGRAPHY IMAGING WITH                                
A MOBILE PHONE 
 
1.1. Introduction 
Chromatography-based methods for separating, detecting and quantifying active 
pharmaceutical ingredients (APIs) in chemical mixtures through their components’ unique 
partition coefficients are fundamental to the field of analytical chemistry [1-3]. One 
specific application for chromatography with important implications for preserving human 
health is identification of falsified and substandard pharmaceutical products [4-6]. The sale 
of falsified and substandard drugs is currently a multi-billion dollar industry, which thrives 
especially in developing countries. According to the World Health Organization, falsified 
and substandard drugs account for up to 30% of sales of pharmaceuticals in developing 
markets [7, 8]. Such products often are produced by highly-organized unscrupulous 
manufacturers who undertake efforts to replicate the physical characteristics such as shape, 
color, and packaging of authentic drug products, but with the active ingredient either 
missing, diluted or completely replaced with another API. These substandard or falsified 
products pose severe health risks for patients who receive doses of an API that are lower 
than that required for efficacy, or receive a substitute API that has no therapeutic indication 
for the disease of concern. The most common incidences of falsified critical drugs are 
encountered in the treatment of malaria, HIV/AIDS, tuberculosis, and cancer; thus these 
 2 
 
products pose an extreme health risk to the patients who take them. For example, an 
estimated 100,000 deaths per year have been linked to the falsified and substandard drug 
trade in Africa [7-9]. Thus, there is an urgent need for an efficient and low-cost technology 
for identification of these products in the drug supply chain. A detection system combined 
with an information-sharing network will enable falsified and/or substandard products to 
be rapidly identified and flagged by their source, batch number, packaging, and physical 
appearance.  
A variety of chromatographic techniques are used for analysis of falsified and 
substandard medicines and illegal pharmaceutical preparations today. Thin layer 
chromatography (TLC), liquid chromatography (LC), gas chromatography (GC), and 
chromatographic fingerprinting are used widely to separate and quantify the chemical 
compounds present in dosage forms, and to subsequently differentiate falsified and 
substandard products from authentic products. Among these approaches, TLC represents 
the simplest and lowest cost approach that is most amenable to adoption in developing 
parts of the world, where expensive laboratory instruments, highly trained staff members, 
and analytical laboratories are not readily available. The physical principles of  TLC 
separation have been thoroughly studied [10, 11], and are summarized in Figure 1.1. 
Testing of an unknown drug compound may be performed by comparison of a TLC profile 
of the unknown compound with calibration profiles. To reduce sources of error, we include 
two such profiles on the same plates as the sample under test. For example, aliquots of a 
drug compound prepared at full concentration (100%) and at a known dilution, e.g., 75% 
of full concentration [12-14], are placed next to an aliquot of an unknown concentration. If 
a drug has been diluted with respect to the full concentration drug, the spot intensity is 
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reduced because the amount of ultraviolet (UV) light absorbed is directly proportional to 
the amount of drug present. Thus, direct comparison of the spot intensity for the unknown 
concentration with the spot intensity of the calibration samples can be used to estimate the 
concentration of an unknown drug. Similarly, the vertical position of a spot in a TLC image 
can be used to verify the identity of a drug in an unknown sample because different 
chemical compounds ascend the plate at different rates. With the advent of affordable 
digital cameras, image-based densitometric evaluation of TLC plates has become prevalent 
[15-17], using desktop instruments that interface with a personal computer. Commercial 
instruments incorporating flatbed scanners, CMOS cameras, white light illumination, and 
high intensity UV lamps have been developed and widely adopted, with prices in the range 
of US $5,000 - 45,000 [18-20]. A large number of applications for an inexpensive handheld 
TLC scanning and image analysis system exist for detection scenarios in food safety, 
pharmaceutical safety, manufacturing quality control, and water quality testing in which 
an immediate result is desired at the point of testing – particularly when a centralized 
laboratory facility is not available.  
Since the introduction of smartphones in 2007, the capabilities of mobile 
technology have rapidly increased in terms of computational power, prevalence of internet 
connectivity, and integration of image sensors with high pixel counts. Advances in mobile 
technology have been accompanied by decreased manufacturing costs, enabling the rapid 
adoption of smartphones to the point that nearly 1.6 B people are estimated to use a 
smartphone [21], with 2014 sales exceeding 1.2 B units [22]. For these reasons, 
smartphones are rapidly being adapted for applications that include healthcare, microscopy, 
and food safety, deriving from the ability to perform assays for disease biomarker detection 
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[23, 24], label-free biosensor measurement [25], fluorometric sensing/imaging [26, 27], 
interpretation of paper test strips [28], and many others [29, 30]. The multi-core processors 
of the most modern smartphones are sufficiently fast to perform on-board image and data 
processing, while cloud-based services can be readily established to log the measurements 
from a community of users, to seek trends in the gathered data, and to communicate the 
results of analysis back to users in real-time. Practical tradeoffs in connectivity, speed, and 
power consumption must be considered when deciding upon the extent to which processing 
is performed directly on the smartphone versus sending data to a remote computer.  
The system employed in this work is comprised of a 3D-printed plastic cradle, a 
Samsung Galaxy Fame smartphone, and a battery-powered UV lamp. The cradle holds the 
phone fixed relative to the 6V UV lamp, enabling capture of 2560 × 1920 pixel (5M pixels) 
images of TLC plates illuminated by 254 nm light. A conventional 100 × 50 mm TLC plate 
is inserted into the cradle through a narrow slot. The system is compact (Figure 1.2), 
lightweight (700 g, including the smartphone and the UV lamp with four 1.5V AA 
batteries), and inexpensive (3D-printed cradle: US $130, handheld UV lamp: US $63, 
smartphone: US $59.99).  
While an inexpensive mobile device was specifically selected for this application 
based on its affordability for applications in drug authenticity screening in resource-limited 
areas, the approach demonstrated in this work may be easily adapted to any mobile device 
with an internal, rear-facing camera. In addition to the detection instrument hardware, we 
have developed a software application (App) that includes an image processing algorithm 
that extracts both vertical location and intensity of three different spots on a TLC plate. For 
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this initial demonstration, we focused our efforts upon TLC analysis of single-component 
drugs, and the ability of our approach to differentiate full-concentration drugs from those 
that have been diluted to 95% and 75% of their full concentration. 75% purity is the lowest 
limit of drug concentration considered acceptable for a single tablet, while many fraudulent 
drug formulations are known to have significantly lower concentrations. In this work, we 
evaluate and compare two approaches for data analysis.  
First, we developed a software application containing an internal image processing 
algorithm that runs efficiently on the smartphone by partitioning every pixel of the TLC 
plate image into one of two classifications (spot or non-spot) and analyzing the absorption 
coefficient of the fluorescence only within the spot locations. Alternatively, a personal 
computer executable program based on an external image processing algorithm that 
operates on a separate computer running Matlab software analyzes the images transferred 
from the smartphone. The external algorithm computes spot intensity by integrating pixel 
values (PVs) in an area of analysis. The retention factor (Rf) is defined as the distance 
between the center of a spot and the origin line normalized to the distance between the 
solvent front line and the origin line. Both image processing approaches require a reference 
image of a blank TLC plate to normalize the effects of non-uniform illumination from the 
UV lamp. The algorithm running in an external computer needs one blank TLC image that 
is pre-stored in the computer for every measurement, while the algorithm running in the 
smartphone requires an image of a blank TLC plate to be taken before each assay. Both 
methods were compared directly to measurements taken with a commercially available 
densitometer (TLC Scanner 3; CAMAG, Muttenz, Switzerland) for a set of TLC plates 
prepared with 100%, 95%, and 75% concentrations of nevirapine (an anti-retroviral 
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product), amodiaquine (an anti-malarial and anti-inflammatory product), and paracetamol 
(an anti-inflammatory product). Our results show that, using either image processing 
method, the smartphone-based TLC system provides measurements for retention factor and 
spot intensity that are equivalent to those taken with the commercial instrument. 
 
1.2. Materials and methods 
The drugs selected for this study are representative of those occasionally targeted 
by fraudulent drug manufacturers and that represent treatments for which severe health 
consequences result for patients who inadvertently take a dose lower than prescribed. 
Paracetamol is a pain reliever and a fever/inflammatory reducer used to treat conditions 
including osteoarthritis, spinal pain, and headache [31]. Nevirapine is a first-generation 
non-nucleoside reverse-transcriptase inhibitor used for the treatment and management of 
HIV/AIDS [32]. Amodiaquine is a drug used for malaria treatment [33]. All three drugs 
are included in the WHO list of essential medicines [34]. Each drug is sold in tablet form, 
and contains a single API that absorbs UV light [35]. Thus, during TLC analysis, each drug 
is expected to produce only a single spot during plate development, and the presence of 
additional spots indicates the presence of undesirable components. Chemicals and reagents 
are briefly described in the Table 1.1 and 1.2.  
 
1.2.1. Preparation of sample stock and working solutions  
The procedures used for performing the TLC spotting and development are 
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described in the Global Pharma Health Fund Minilab®  manuals [36]. One tablet 
(paracetamol 500 mg, amodiaquine 200 mg, or nevirapine 200 mg) was ground into a fine 
powder while wrapped in aluminum foil, and the powder was transferred into a 100 mL 
volumetric flask containing 40 mL of methanol. The flask was shaken for three minutes to 
dissolve the API and was set to stand for approximately five minutes to allow the 
undissolved residue to settle leaving a clear supernatant liquid. Appropriate amounts of 
methanol were then added to the flask to obtain the target of 5 mg/ml. Aliquots were drawn 
from the supernatant stock sample solutions to prepare 100%, 95%, and 75% solutions 
(Table 1.1).  
 
1.2.2. Chromatography and densitometric scanning  
The solvent front line was pre-marked at 70 mm from the bottom of the TLC plate. 
Two microliters of the test solutions were manually placed on the plate along the origin 
line as a spot using precision 2 μl capillaries. After spotting, the plates were air-dried and 
then placed into the developing jar. The developing jar was lined with filter paper on one 
long side to aid saturation, and the mobile phase was poured into the jar. The composition 
of the mobile phase for each drug is shown in Table 1.2. The jar lid was closed for 20 
minutes to saturate the tank before the plate was developed. After the plate was placed into 
the jar and the mobile phase front proceeded to the pre-marked solvent front line, the plate 
was removed and allowed to dry for three to five minutes. After drying, the plates were 
scanned using the conventional densitometer (UV illumination: λpeak = 254 nm). The 
detector slit parameters were set at 6 × 0.45 mm, the scanning speed was set at 20 mm/s, 
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and the data resolution was set at 100 μm/step. The data capture and calculations obtained 
from the scanned plates were performed with the instrument-supplied planar 
chromatography manager software (winCATS 1.4.3; CAMAG).  
 
1.2.3. Smartphone TLC analyzer  
A schematic of the system and a photo of the captured image are shown in Figure 
1.3. A custom-designed cradle that is fabricated using a 3D-printer (Objet350 with polyjet 
material Vero; Stratasys, MN, USA) aligns the smartphone (S6812; Samsung, Seoul, South 
Korea), the UV lamp (254 nm Handheld Mini UV Lamp; UVP, CA, USA), and the TLC 
plate. The smartphone’s rear-facing camera is aligned with a plate guide that places the 
TLC plate into focus and into the camera field of view (Figure 1.4). The TLC plates are 
inserted into the cradle body via a small entrance slit placed in front of the cradle, and a 
guide holds the plate down flat. The distance from the camera to the plate is 100 mm. The 
cradle provides a dark environment that prevents external light sources from degrading the 
integrity of the TLC images. The UV lamp is removable and is installed using the 
positioning holes of the cradle body and lid to fix it securely in place. The UV lamp is 
oriented at a 39° angle with respect to the TLC plate surface in order to provide UV 
illumination over a wide surface area, although, due to the intrinsic geometry of the lamp, 
the illumination intensity is greatest along the central axis, and falls off smoothly as one 
moves away from the central axis. The spots formed by drugs on the TLC plates cannot be 
observed without UV light (Figure 1.5(a)). However, as Figure 1.5(b) shows, when the 
plate is illuminated with the UV light, the fluorescent compound emits green light that is 
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reduced in intensity by the UV-absorbing APIs, resulting in dark spots on a bright green 
background. Figure 1.5(c) depicts the fluorescent intensity distribution over the plate. The 
area of image analysis is approximately 40 × 80 mm, which is comprised of 1020 × 2060 
pixels, enabling the entire plate area beyond the origin line to be analyzed.  
 
1.2.4. Image processing: external algorithm  
An unprocessed RGB (red, green, blue) photo taken by the smartphone is 
comprised of a matrix of 2560 × 1920 × 3 pixels (the smallest resolvable image elements). 
The first two dimensions represent the size of the photo, and the last dimension provides a 
24-bit RGB color space. Each of the RGB intensity components of each pixel is stored as 
an 8-bit unsigned integer, giving a range of 0 to 255. A flow chart of the automated 
processing is shown in Figure 1.6. First, data acquisition is performed when a user initiates 
a scan, for which a sequence of 10 nominally identical images of the plate is acquired in 
series (1 photo / 1 sec, ISO 400, exposure -4). Compared to colorimetric analysis using 
each RGB channel independently, we analyze the total light intensity, as the fluorescent 
emission of the TLC plate is comprised of only a narrow band of wavelengths in the green 
channel. To extract the green fluorescence intensity levels from a color image, we apply a 
colormap transformation to change the color image in its RGB color space to its 
representation in YIQ color space that is more sensitive to changes in luminosity by the 
following transform [37].  
[
  𝑌 = 0.2989𝑅 + 0.5866𝐺 + 0.1144𝐵  
 𝐼 = 0.5959𝑅 − 0.2741𝐺 − 0.3218𝐵 
 𝑄 = 0.2113𝑅 − 0.5227𝐺 + 0.3113𝐵 
] 
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 In the YIQ system, the Y-channel carries information of perceived relative 
brightness of different colors, while I- and Q-channels are jointly related to the hue and 
saturation components of a color space. We select the Y-channel image represented by a 
2560 × 1920 × 1 matrix for the TLC plate analysis because the light intensity variation due 
to spots on the TLC plate is mostly captured in the Y-channel. Next, 10 Y-channel images 
are averaged to generate a single image (Figure 1.6(a-c)). Images captured via CMOS 
sensors suffer from various noise sources, including shot noise, thermal noise, and readout 
noise, that can generate undesired standard deviation for low-intensity images if only a 
single image is used [38]. Image averaging reduces the impact of these noise sources 
without compromising spatial detail of the original image because it increases an image’s 
signal-to-noise ratio (SNR) [39]. As shown in Figure 1.6(d), the stored Y-channel image of 
a blank TLC plate is subtracted from the averaged Y-channel image to remove the effect of 
uneven illumination resulting from the irregular spatial intensity distribution of UV light 
and the tilted orientation of the lamp. The TLC plate markings (the solvent front line and 
the origin line) are also easily distinguished after the subtraction and can be located by our 
image processing algorithm, which measures the minimum pixel value when scanned in 
the vertical direction with a 10-pixel offset from both sides, while avoiding the spots 
(Figure 1.6(e)). The analysis area for three different spots is defined as a rectangular box 
whose edges are matched to a threshold value (Th), 0.45, around a spot of 100% drug 
concentration (Figure 1.6(f,g)). The threshold value is set by considering overall 
background noise, where the largest nonspecific noise observed has a pixel intensity 
ranging from 0.5 (green pixel) to 1 (red pixel). We set 0.05 (10% of 0.5) of extra margin 
to improve the robustness of classifying a pixel as either “spot contributed (PV ≤ 0.45)” or 
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“background noise (PV > 0.45)”. The analysis area is well matched with the relevant size 
of the full concentration spot, and a center of the analysis area is considered as the center 
of the spot. The retention factor Rf of each spot is then measured as the ratio of the vertical 
distance traveled to the distance between the solvent front and origin lines, as shown in the 
following equation: 
𝑅𝑓 =  
𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒 𝑡𝑟𝑎𝑣𝑒𝑙𝑒𝑑 𝑏𝑦 𝑡ℎ𝑒 𝑝𝑟𝑖𝑛𝑐𝑖𝑝𝑎𝑙 𝑠𝑝𝑜𝑡 
𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒 𝑡𝑟𝑎𝑣𝑒𝑙𝑒𝑑 𝑏𝑦 𝑡ℎ𝑒 𝑠𝑜𝑙𝑣𝑒𝑛𝑡 𝑓𝑟𝑜𝑛𝑡
 
 
=  
# 𝑜𝑓 𝑝𝑖𝑥𝑒𝑙𝑠 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑡ℎ𝑒 𝑠𝑝𝑜𝑡′𝑠 𝑐𝑒𝑛𝑡𝑒𝑟 𝑎𝑛𝑑 𝑡ℎ𝑒 𝑜𝑟𝑖𝑔𝑖𝑛 𝑙𝑖𝑛𝑒
# 𝑜𝑓 𝑝𝑖𝑥𝑒𝑙𝑠 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑡ℎ𝑒 𝑠𝑜𝑙𝑣𝑒𝑛𝑡 𝑓𝑟𝑜𝑛𝑡 𝑙𝑖𝑛𝑒 𝑎𝑛𝑑 𝑡ℎ𝑒 𝑜𝑟𝑖𝑔𝑖𝑛 𝑙𝑖𝑛𝑒
 
 
The process for characterizing the spot intensity is shown in Figure 1.6(h). Among 
the pixels within the analysis domain, those with values below the Th are selected as 
constituting a “principal spot” first. Then, to remove nonspecific singular noise, pixels with 
values less than a 10%-offset cutoff are ignored because several pixels reach to very small 
PV occasionally and they contribute to an inaccurate spot intensity computation. This 
cutoff value is defined by:  
10%-offset = min. PV + (Th – min. PV) / 10 
where the min. PV is the absolute minimum pixel value within the analysis domain. The 
pixel values that lie within the band, between the Th and the cutoff, are integrated in order 
to have the spot intensity described by the equation:  
𝑆𝑝𝑜𝑡 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 = ∑ ∑ 𝑃𝑉𝑖,𝑗
𝑝𝑥2
𝑖=𝑝𝑥1
𝑝𝑦2
𝑗=𝑝𝑦1 
  (𝑖𝑓 𝑐𝑢𝑡𝑜𝑓𝑓 ≤ 𝑃𝑉𝑖,𝑗 ≤ 𝑇ℎ) 
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where the px1/px2 are pixel indices corresponding to the both vertical edges of the analysis 
area, while the px1/px2 are pixel indices corresponding to the both horizontal edges. All 
three spots are analyzed using the approach described (Figure 1.6(i)).  
 
1.2.5. Image processing: internal algorithm  
The flow chart of the internal algorithm is shown in Figure 1.7. For detecting lines 
and segmenting out spots, luminance matters most, as described in the External Algorithm 
section. The internal algorithm thus follows the same first steps (Figure 1.6(a-c)) to 
compute an average luminance (Y) image (1 photo / 1 sec, ISO 200, exposure 2). Our 
detection algorithm for determining the position of the origin line and solvent front line is 
derived from edge detection algorithms [40] with an assumption that these lines are parallel 
to the top and bottom edges of the TLC plate. First, we blur the TLC image by filtering the 
TLC image by a 2D Gaussian filter with sigma of four. This step smooths the image and 
removes high frequency noise. However, the lines that we need to detect belong to the high 
frequency part of the image as well. Therefore, we face a tradeoff between blurring and 
localizing the edges. The tradeoff is determined by the width (sigma) of the Gaussian filter. 
Sigma of four works well for our dataset in terms of blurring the image without losing the 
localization of the edges. Also, when applying a 2D Gaussian filter, it is customary to 
choose a filter size of six sigma with an odd width and height for symmetry with the central 
peak. With sigma of four, our filter size is 25 by 25. After smoothing with the Gaussian, 
we filter the resulting image with the filter [1 -2 1]T. This step serves the purpose of taking 
the second derivative of the image in the vertical direction. Since we assume that lines are 
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parallel to the top and bottom edges of the TLC plate, we sum the result of the previous 
step in the horizontal direction in order to make the final localization step easier. In order 
to localize lines in the last step, we search for the positions of the two strongest local peaks. 
A local peak is defined as a data sample larger than its two neighbors. The peak near the 
top of the image corresponds to the solvent front, and the peak near the bottom of the image 
corresponds to the origin. The front line and origin line detection algorithm is summarized 
as Algorithm 1 shown below. 
Algorithm 1: Origin and Solvent Front Detection 
1. Filter the TLC image by 2D Gaussian filter with sigma of four.  
2. Filter the result of step 1 with filter [1 -2 1]T. 
3. Horizontally sum the result of step 2.  
4. Search for the positions of two strongest local peaks. The peak near the top of the 
image corresponds to the solvent front, and the peak near the bottom of the image 
corresponds to the origin. 
 
 
An instance of executing the algorithm is illustrated in Figure 1.7(a-d). After locating the 
origin line and the front line, we crop them from the original image and use the cropped 
original for the spot detection step.  
Spots are comprised of the lowest intensity pixels in a TLC image. Therefore, we 
choose to employ global thresholding [40], which means using a threshold to convert an 
image into a binary image. Pixels with values at or above the threshold are assigned a value 
of 1, and pixels with values below the threshold are assigned a value of 0. Global 
thresholding is simple, fast, and requires minimal computational resources. However, 
variations in the UV illumination intensity across the plate cause problems with direct 
application of global thresholding. We correct for this effect by multiplying the image by 
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the inverse of a blank plate image. Figure 1.7(e) illustrates the result of this normalization 
step. Note that some normalized pixels have intensity values greater than unity, which 
occurs for two reasons. First, limitations of the phone camera such as dynamic range, lack 
of auto exposure locking, and lack of white balance locking can result in images of a blank 
plate and a developed plate starting on different Y-channel intensity bases. Second, a blank 
plate may not be an identical replica of the TLC assay plate; thus the blank plate may have 
slightly different fluorescence intensity. After blank plate correction, we segment out spots 
by setting a threshold that separates out the darkest 4% pixels. This threshold was chosen 
experimentally using several plates in our dataset, then shown to be effective for the 
remaining plates in the dataset, which results in good visual results for spot segmentation. 
We further clean up noise in the binary image using a morphological image processing 
technique. Figure 1.7(f) illustrates the final result of segmentation.  
At this stage, we have a binarized image with spots separated from the background. 
Spots are then located using a connected component algorithm [40] with eight connectivity, 
which means that any two pixels are considered connected whenever they are adjacent in 
horizontal, vertical, or diagonal directions. We then extract data from the resulting 
components (each is a spot). In order to find the center of a spot, we draw a bounding box 
around the spot and sum the region in both the vertical and horizontal directions. The center 
coordinates are located by finding the minima of fitted quadratic curves to those 1D 
summed signals. We could use the center of the box as the center of the spot, but spots 
generally appear as ellipses, so fitting gives more accurate estimates of the center. From 
the center position of each spot, we can derive the spot position value for each spot, 
representing the distance between the center of the spot and the origin line divided by the 
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distance between solvent front and the origin line. The entire algorithm is summarized as 
Algorithm 2 shown below. 
Algorithm 2: Spot detection 
1. Multiply the image by the inverse of a blank plate image to obtain the corrected 
illumination image.  
2. Compute a histogram of image brightness and select a threshold to separate the darkest 
4% of pixels. 
3. Use global thresholding to obtain a binary image based on the 4% threshold. 
4. Apply binary opening mathematical morphological operators with disk structure 
element of radius 15. 
5. Locate spot regions using a connected components algorithm with eight connectivity. 
This step produces mask images for each spot. 
6. Using the mask for each spot in step 5, extract spot data from corrected illumination 
image from step 1. 
7. For a spot, draw a bounding box around it, then locate the center coordinates by finding 
the minimums of fitted second polynomial curves to the horizontal and vertical sum of 
the region. 
8. Derive the Rf value for each spot. 
 
The amount of UV light absorbed depends on the amount of API present on the 
TLC plate, which in turn depends on the concentration of the sample aliquot. Lower 
concentrations absorb less UV light and produce lighter spots, while higher concentrations 
absorb more light and produce darker spots. To quantify relative concentration, we 
integrate the absorption values of the 400 lowest pixel intensities inside the spot. The 
number 400 was chosen empirically based on our test TLC plates. The absorption value is 
measured as 1-pixel intensity, where pixel intensity ranges from 0 to 1. Since the TLC 
image that we obtain from the camera is in RGB color space, we developed a technique to 
make use of all channel information. Mathematically, for each pixel of the plate image, the 
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normalized result is a dot product between a three-element vector (A1, A2, A3) and red, 
green, blue pixel intensity of the TLC plate subject to the constraint that: 
𝐴1𝑅𝑏𝑔 +  𝐴2𝐺𝑏𝑔 + 𝐴3𝐵𝑏𝑔 = 1 
 
where Rbg, Gbg, Bbg are red, green, blue intensity values of the blank plate. Algorithm 3 
shown below summarizes the spot differentiation process as well as optimal values of A1, 
A2, and A3. 
Algorithm 3: Spot differentiation 
1. Normalize the intensity of each spot with the corresponding region of the blank plate 
using the formula in Proposition 1. 
2. Integrate the absorption of the 400 lowest intensity pixels inside each spot. At a 
specific pixel location, if the normalized intensity is a, absorption is then 1 – a. 
3. Based on the absorption values, differentiate spots. 
 
Definition 1: Normalization 
For each pixel in an RGB image and a three-element vector  (𝐴1,  𝐴2, 𝐴3) , a 
normalization is a dot product between (𝐴1, 𝐴2,  𝐴3) and the three-element (R, G, 
B) pixel intensity vector of that pixel.  
 
Proposition 1: 
Given the normalization definition in Definition 1, for each pixel, if 
𝑅𝑏𝑔,  𝐺𝑏𝑔,  𝐵𝑏𝑔 are red, green, blue intensity values of the blank plate and R, G, B 
are the corresponding red, green, blue intensity values of the sample plate, then the 
error on the normalization of the sample plate is minimized when parameters A1, 
A2, A3 are chosen as: 
 
𝐴1 =
𝑅𝑏𝑔
𝑅𝑏𝑔
2 + 𝐺𝑏𝑔
2 + 𝐵𝑏𝑔
2  
 
𝐴2 =
𝐺𝑏𝑔
𝑅𝑏𝑔
2 + 𝐺𝑏𝑔
2 + 𝐵𝑏𝑔
2  
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𝐴3 =
𝐵𝑏𝑔
𝑅𝑏𝑔
2 + 𝐺𝑏𝑔
2 + 𝐵𝑏𝑔
2  
 
Proof: 
We assume quantization noise Q dominates other noise sources and is a constant. 
Since error on R, G, and B is Q, error on the normalized result is: 
 
 
𝐴1
2(∆𝑅)2 + 𝐴2
2(∆𝐺)2 + 𝐴3
2(∆𝐵)2 = 𝐴1
2𝑄2 + 𝐴2
2𝑄2 + 𝐴3
2𝑄2 = (𝐴1
2 + 𝐴2
2 + 𝐴3
2)𝑄2 
 
 
We need to pick (𝐴1, 𝐴2, 𝐴3) to minimize (𝐴1
2 + 𝐴2
2 + 𝐴3
2). 
According to Cauchy–Schwarz inequality: 
 
 
        (𝐴1
2 + 𝐴2
2 + 𝐴3
2)(𝑅𝑏𝑔
2 + 𝐺𝑏𝑔
2 + 𝐵𝑏𝑔
2 )  ≥  (𝐴1𝑅𝑏𝑔 +  𝐴2𝐺𝑏𝑔 + 𝐴3𝐵𝑏𝑔)
2
= 12 = 1 
 
         ↔ 𝐴1
2 + 𝐴2
2 + 𝐴3
2  ≥   
1
𝑅𝑏𝑔
2 + 𝐺𝑏𝑔
2 + 𝐵𝑏𝑔
2  
 
 
Equality happens at 𝐴1, 𝐴2,  𝐴3 stated. 
 
 
1.3. Results and discussion 
The smartphone-based TLC analyzer was used to measure two primary 
characteristics, spot intensity and retention factor Rf, of a target sample with different 
concentrations (100%, 95%, and 75%). Three different drugs (amodiaquine, nevirapine, 
and paracetamol) were tested to evaluate the system via direct comparison with the analysis 
provided by the commercial TLC reader.  
The analysis results from a plate developed with paracetamol using the smartphone 
TLC analyzer are shown in Figure 1.8. The final processed results are displayed to users 
by the external algorithm and by the internal algorithm. Drug quality can be evaluated 
using spot intensity, while drug identity is verified by retention factor. By comparing the 
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spot intensity resulting from the unknown sample to the calibration samples (100%: 
standard quality, 75%: minimum acceptable quality), a decision on whether the unknown 
sample is acceptable can be rendered. When 95%-drug is tested among the references, the 
spot intensity is positioned between those of the reference spots. Whether an unknown 
sample contains the desired API can be determined by comparing the Rf of the unknown 
with the Rf of the calibration samples. For qualitative analysis, there is strong evidence that 
the drugs in the test and standard solution are identical if the principal spots of both samples 
show the same Rf  values. The measurement conducted on the smartphone is guided by the 
software application’s text instructions through the whole process while the analysis 
implemented on the computer is processed using Matlab software.  
Three replicates of a plate loaded with paracetamol were prepared to evaluate the 
reproducibility of the plate preparation process in which there may be inherent errors 
resulting from the manual placement of spots (Table 1.3). The principal spot intensity and 
travel distance can vary from plate to plate due to experimental variants like sample 
spotting, solvent mixing, and plate development. The coefficient of variation (CV) is 
defined as CV = σ / μ, where the σ represents the standard deviation, and μ is the mean. 
Both laboratory TLC densitometer and external algorithm yield the same CV for three 
independent measurements of the Rf. We obtained CV values of 3%, 1.2%, and 1.2% for 
100%, 95%, and 75% drug concentrations, respectively. The CV values for the spot 
intensity measured by the external algorithm for the same spots were 4.9%, 3.0%, and 4.9%, 
while those for the same spots measured with the densitometer were 1%, 0.2%, and 1.8%. 
These results are typical for the reproducibility of TLC measurements of plates prepared 
 19 
 
by a well-trained operator. Generally, we found that the CVs obtained with the smartphone-
based measurement agree well with those obtained with the laboratory TLC densitometer.  
Next, we demonstrated the repeatability of our measurements by removing the 
paracetamol-loaded TLC plate from the cradle and then inserting it again. Figure 1.9 shows 
10 overlaid results from these measurements using both the external and internal 
algorithms. The external algorithm shows that, when the spot intensity of the 100% 
calibration drug is normalized to 1, a mean spot intensity of 95% drug is measured to be 
0.832 (standard deviation (σ) = 0.013) and that of 75% drug is 0.579 (σ = 0.026), while the 
internal algorithm shows 0.939 (σ = 0.001) and 0.921 (σ = 0.003), respectively. Even 
though the internal algorithm provides narrow dynamic range for the spot intensity in 
comparison with the external algorithm, the standard deviation is small enough for the 
internal algorithm to detect 5% difference of the drug quality. In every measurement, the 
Rf values measured by the external algorithm were consistently found to be 0.40. The Rf 
values processed by the internal algorithms varied from 0.4 to 0.41 (σ95% = 0, σ75% = 0.001). 
The UV lamp output is not robustly stable and the plate is not placed at the exact same 
position every time, resulting in small differences in spot intensity over 10 independent 
measurements due to the fact that spot intensity is measured based on pixel intensity 
analysis. However, the illumination and location do not affect the determined retention 
factor, and the spot intensity is still proportional to the drug quality. Figure 1.10 compares 
the paracetamol spot characteristics from a single TLC plate measured by both the 
smartphone TLC analyzer and the densitometer. Both algorithms show similar trends of 
spot intensity reduction as the drug concentration decreases, while the Rf values are almost 
the same. The error bars represent three standard deviations (3σ).  
 20 
 
Three drugs were tested and compared using the densitometer and the smartphone 
TLC analyzer (Table 1.4). Spot intensities and travel distances measured with the 
smartphone TLC analyzer were averaged over 10 independent measurements. An analysis 
of one TLC plate takes 14 s for the external algorithm running on a 3.4 GHz Intel i7-2600 
processor and 30 s for the internal algorithm running on a 1 GHz Cortex-A9 processor, 
resulting in a one-hour drug test including sample preparation. As shown, both approaches 
used with the smartphone TLC analyzer provide results similar to those from the 
commercial TLC reader. Although the non-uniform illumination from the UV lamp is 
intrinsic to the instrument, the effects of inhomogeneous light distribution are negligible 
by adopting the normalization processing with a blank TLC plate, as shown in 4S(d) and 
5S(e). This approach utilizes the entire plate areas, and any Rf values between 0 ~ 1 can be 
measured regardless of the uneven excitation over the plate. The quality of diluted drugs 
was distinguishable from that of the standard drug by comparing the normalized spot 
intensities. In particular, lower drug concentrations produce lower spot intensity values, 
and the lowest drug concentration provides the smallest spot intensity value. The 
smartphone TLC analyzer can discern 5% differences in concentration, as can the 
densitometer. This is sufficiently high resolution because there is 25% margin for 
acceptable drug quality. When falsified pharmaceutical product contains more than 100% 
of the API concentration, excess of the API would be reported because the spot intensity 
would be higher than that of the calibration sample (100%). The Rf values measured by the 
external algorithm were the same as those measured by the densitometer, while the internal 
algorithm gave slightly higher, but consistent, Rf values to identify the drugs. Each drug 
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shows its own specific Rf value. These characteristic Rf values can be pre-stored to identify 
an unknown sample without the use of calibration samples. 
 
1.4. Conclusion 
In this work, we have reported the first demonstration of quantitative analysis of 
pharmaceutical compounds using a mobile phone TLC analyzer. By integrating a UV lamp 
and the TLC plate in a 3D-printed plastic cradle that can be easily interfaced with a mobile 
phone, the system serves as a portable scanner for performing TLC plate analysis for 
identification of falsified and substandard pharmaceutical products. This cost-effective, 
compact, and portable TLC plate scanning platform integrated with a mobile phone permits 
direct visualization of principal spots on the plate prepared with fluorescent compound and 
provides spot intensity and retention factor Rf of each spot to facilitate verifying identity 
and determining an API’s quality. We have demonstrated operation of the system by the 
analysis of three different drugs (nevirapine, amodiaquine, and paracetamol) diluted to 
100%, 95% and 75% of their full concentration. The same approach is applicable to any 
UV-absorbing API. Two robust image processing frameworks that can be used with an 
external computer or via an application that runs on an inexpensive smartphone’s internal 
processor were developed to provide a range of options considering the practical tradeoffs 
in wireless network connectivity, image processing speed, and power consumption. Both 
algorithms were built to overcome the SNR challenges inherent in automated interpretation 
of TLC spot images, and allow quantitative measurements of principal spots imaged on the 
smartphone TLC analyzer, achieving detection of 5% drug concentration differences, 
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representing the same capability as a laboratory-based desktop TLC densitometer. 
Although not all drug compounds are UV-active, this mobile phone-based TLC plate 
scanning platform provides a unique solution for analyzing the contents of UV-absorbing 
pharmaceutical substances and can be utilized for verifying the authenticity of APIs using 
a distinct capability that is widely available in resource-limited settings or remote areas 
that lack access to a densitometer instrument. 
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1.5. Figures 
 
 
Figure 1.1. Illustration of TLC plate development process. TLC utilizes a solid substrate 
support (most commonly a 200 μm thick strip of aluminum) that is coated with a stationary 
phase (silica gel, layer thickness: 200 ~ 250 μm). The stationary phase is infused with a 
fluorescent indicator compound (manganese activated zinc silicate) that emits a broad band 
of wavelengths in the green part of the visible spectrum when excited by UV light (λ = 254 
nm). The substrate and stationary phase constitute the TLC plate. TLC plates are mass-
manufactured in standard size format, and the conventional format used in our work is 50 
× 100 mm. Chromatographic separation using TLC is initiated by manually spotting 
aliquots of the drug sample and the references along an origin line placed 15 mm from one 
edge. The origin line is marked with a horizontally-drawn pencil line. After the spots dry, 
the plates are placed into a developing solution (mobile phase) in a closed jar. The mobile 
phase travels vertically along the stationary phase via capillary action. As the mobile phase 
moves past the origin line, the drug components are drawn upwards and travel with the 
mobile phase through the stationary phase at different rates depending on their molecular 
polarities. The distance that the mobile phase front (or solvent front) should travel during 
the test is typically marked with a pencil-drawn line before the plate development. The 
TLC plate development is stopped when the mobile phase reaches this line. The plate is 
then removed from the jar and allowed to dry. Even though the principal spots are not 
visible without UV illumination, they will be located between the origin line and the 
solvent front line. This TLC development process takes an hour. 
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Figure 1.2. Mechanical dimensions of 3D-printed cradle. (a) Body. (b) Cover. The 
cradle holds a smartphone, a UV lamp, and a TLC plate and aligns them to take an image 
of principal spots on the TLC plate under UV illumination. Size of the camera hole is 10.5 
× 10.5 mm. The TLC plate guide is sufficiently long (93 mm) to have the image of most 
areas of the plate. The cover supports one side of the lamp and provides a dark environment. 
The openings and positioning blocks help fix the UV lamp. When the lamp is assembled, 
its body blocks most areas of the openings to prevent intervention of any external light 
sources into the cradle. Lengths are specified in the drawing. 
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Figure 1.3.  Illustration of the smartphone TLC analyzer and photographs of the 
system. (a, b) Illustration of the cradle that holds a smartphone, a UV lamp, and a TLC 
plate. (c) Illustration of the cover provides a dark environment and that mechanically 
supports the lamp. (d) Photo of the assembled smartphone TLC analyzer. (e) Photo of the 
TLC plate analysis (image capturing/processing). (f) Captured full image of the TLC plate. 
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Figure 1.4. Cross section of smartphone TLC analyzer. A smartphone camera, a UV 
lamp, and a TLC plate are well aligned to illuminate the plate and take an image of it. When 
the UV light excites the fluorescent compound that is embedded on the TLC plate, it emits 
green fluorescence. The image of principal spots (weakened fluorescence area due to the 
presence of sample drugs) surrounded by green background is captured by smartphone 
camera via the camera hole. The captured image can be processed by an app run on the 
smartphone or by an external computer connected via wireless network. 
 
 
Figure 1.5. TLC plate images after development. (a) Visible light. (b) With UV 
illumination. (c) Distribution of fluorescence intensity. 
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Figure 1.6. Flow chart of automated chemical constituent quantification (external 
algorithm). (a) Sequence of photos of a TLC plate, captured by mobile phone’s rear-facing 
camera. (b) Y channel image extracted from the YIQ colormap. (c) High SNR image 
obtained by averaging of the photos captured in (a). (d) A processed image for which the 
effects of uneven illumination are eliminated by subtraction of the background from a blank 
plate. (e) Detection of the solvent front line and the origin line. (f) Detection of spot centers, 
retention factor, and analysis area. (g) Pixel-by-pixel analysis within the area defined in (f). 
(h) Integration of pixel values, which are between the threshold and the offset point, to 
define spot intensity. (i) Comparison between three spots. 
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Figure 1.7. Flow chart of automated chemical constituent quantification (internal 
algorithm). (a) Luminance (starting from Figure S4(c)). (b) Result of filtering by Gaussian 
filter with sigma of four. (c) Result of horizontally summing filtered response. (d) Result 
of line detection algorithm. (e) Result of multiplying the image by the inverse of a blank 
plate image. (f) Result of converting (e) into a binary image by using a global threshold. 
 
 
 
(a)                    (b)                   
(d)                    (e)                                                (f)                 
(c)  
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Figure 1.8. TLC plate image analysis. Final results are displayed (a) on the phone’s 
display screen by the external algorithm and (b) by the internal algorithm. Spot intensities 
(SI in (a) and I in (b)) and retention factors Rf, representing the analysis values that 
represent the darkness and location of spots. When an unknown sample is loaded between 
the two references (100% and 75%), the quality/identity of the unknown sample can be 
easily verified by simple comparison with the references. 
 
 
 
 
 
 
 
 
 
(a)                                    (b)                 
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Figure 1.9.  Results from 10 independent measurements of a paracetamol TLC plate 
taken by removing and re-inserting the plate into the cradle, demonstrating excellent 
measurement reproducibility. Normalized spot intensities and travel distances (Rf) 
measured by the external algorithm (a, b) and by the internal algorithm (c, d). 
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Figure 1.10.  Normalized spot intensity/travel distance (Rf) measurements and comparison 
with measurements of the same plate taken with a densitometer for a TLC plate prepared 
with paracetamol spots. 
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1.6. Tables 
Table 1.1. Summary of sample stock and working solution concentrations  
 
Pharmaceutical product 
Stock sample 
solution [mg/ml] 
Working sample solutions [mg/ml] 
100% 95% 75% 
Paracetamol 5.0 1.25 1.19 0.94 
Amodiaquine 5.0 0.63 0.59 0.47 
Nevirapine 5.0 1.25 1.19 0.94 
 
* The amounts of API added depended on the absorptivity of the compound; the higher 
the absorptivity the lower the concentration to keep the quench at an optimum level.   
 
 
Table 1.2. Mobile phase composition ratio 
 
Pharmaceutical product 
Composition ratios 
Ethyl acetate Toluene Methanol Ammonia 
Paracetamol1 24 ∙ 3 1 
Amodiaquine2 10 ∙ 40 1 
Nevirapine3 11 4 5 ∙ 
 
1Pharmweb Web site. http://www.pharmweb.net/pwmirror/library/tlc/tlcall.pdf (accessed Dec 26, 2015).  
2GPHF-Minilab Web site. http://www.gphf.org/images/downloads/previous_manuals/manual_2_vol4_en. 
pdf (accessed Dec 26, 2015).  
3GPHF-Minilab Web site. http://www.gphf.org/images/downloads/previous_manuals/manual_2_vol3_en. 
pdf (accessed Dec 26, 2015).  
  
 33 
 
Table 1.3. Analysis and comparison of TLC analyzers using paracetamol loaded on three 
separate plates 
 
Plate 
Number 
Measurements Drug Conc. Densitometer 
Smartphone TLC Analyzer 
External Internal 
1 
Spot Intensity 
(A.U.) 
100 % 10719 793 267.67 
95 % 9853 660 251.33 
75 % 8905 459 246.46 
Travel 
Distance (Rf) 
100 % 0.40 0.40 0.41 
95 % 0.40 0.40 0.41 
75 % 0.40 0.40 0.40 
2 
Spot Intensity 
(A.U.) 
100 % 10786 866 268.41 
95 % 9871 636 252.07 
75 % 9182 436 248.91 
Travel 
Distance (Rf) 
100 % 0.41 0.41 0.41 
95 % 0.41 0.41 0.41 
75 % 0.41 0.41 0.41 
3 
Spot Intensity 
(A.U.) 
100 % 10540 773 266.77 
95 % 9829 614 251.09 
75 % 8804 407 245.32 
Travel 
Distance (Rf) 
100 % 0.43 0.43 0.43 
95 % 0.41 0.41 0.41 
75 % 0.41 0.41 0.41 
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Table 1.4. Analysis and comparison of TLC analyzers using three different drugs 
Drugs Measurements 
Drug 
Conc. 
Densitometer 
Smartphone TLC 
Analyzer 
External Internal 
Amodiaquine 
Normalized 
Spot Intensity 
100 % 1 1 1 
95 % 0.958 0.906 0.980 
75 % 0.932 0.755 0.941 
Travel Distance 
(Rf) 
100 % 0.73 0.73 0.74 
95 % 0.73 0.73 0.74 
75 % 0.73 0.73 0.73 
Nevirapine 
Normalized 
Spot Intensity 
100 % 1 1 1 
95 % 0.938 0.817 0.974 
75 % 0.806 0.771 0.947 
Travel Distance 
(Rf) 
100 % 0.61 0.61 0.62 
95 % 0.61 0.61 0.62 
75 % 0.61 0.61 0.62 
Paracetamol 
Normalized 
Spot Intensity 
100 % 1 1 1 
95 % 0.919 0.832 0.939 
75 % 0.831 0.579 0.921 
Travel Distance 
(Rf) 
100 % 0.40 0.40 0.41 
95 % 0.40 0.40 0.41 
75 % 0.40 0.40 0.40 
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CHAPTER 2 
SMARTPHONE-BASED MULTIPLEXING                          
PATHOGEN DETECTION OF INFECTIOUS DISEASES 
 
2.1. Introduction 
Infectious diseases, such as HIV/AIDS, tuberculosis, and malaria, while accounting 
for less than 10% of deaths in the developed world, are responsible for more than half of 
all deaths in developing countries [41]. A contributing factor to the mortality of infectious 
diseases in developing countries is that co-infection by more than one pathogen carries 
greater risk than a single infection, while many assays that only test for one agent could 
miss the presence of a co-infection. Despite recent progress in the development of new 
drugs for treatment of viral, bacterial, and fungal infections [42], the worldwide death toll 
continues to rise with critical needs for increased understanding of fundamental disease 
mechanisms, and enhanced point-of-care diagnostics. Importantly, there is a need for 
improved surveillance tools that can detect the emergence of drug resistance, alert 
clinicians to the initiation of a potential outbreak, monitor the effectiveness of quarantines, 
and facilitate cross-communication between clinicians who are geographically distributed. 
For human infectious diseases in the US, approximately 55 million people are designated 
as “reportable” by the Centers for Disease Control, which requires a positive laboratory 
test to be communicated to central authorities, although the information is reported to 
clinicians by the National Notifiable Diseases Surveillance System (NNDSS), which is 
most heavily utilized only for the most deadly disease outbreaks [43].  Most forms of 
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influenza have no reporting requirement, and thus no information is gathered or 
communicated for human respiratory infectious diseases that are responsible for 2-3 
million cases and 250,000 – 500,000 deaths worldwide each year [44]. Reporting 
requirements are even more rudimentary in the developing world, largely depriving 
clinicians of a global view of the incidence, spread, and control of infectious diseases that 
affect their community. 
The societal and economic toll of infectious disease is not limited only to human 
populations.  Animals raised for human consumption live in facilities in which large herds 
share ventilation, feed, and waste handling within confined spaces in which respiratory 
infectious disease can spread rapidly. Similar concerns exist for companion animals and 
racing animals, particularly for those with high economic value.  In veterinary medicine in 
the US, only a handful of infectious diseases are categorized as “reportable” by the USDA, 
requirements vary from state to state, and no cross-communication infrastructure exists that 
enables veterinarians to easily share results with each other. 
A key characteristic of a successful system for monitoring and reporting of 
infectious disease is its diagnosis speed. For example, modeling studies on various 
intervention strategies for pandemic influenza response have shown that the highest impact 
on attack rate is obtained by identification and initiation of treatment one day earlier [45]. 
Particularly for point-of-care (POC) scenarios, where the clinician is testing a patient at a 
remote clinic, a farm, or a racetrack, the need to send samples to a central laboratory, to 
wait for the test to be performed, and to wait for the results to be reported, results in an 
enormous waste of opportunity to determine if aggressive treatment or quarantine is needed 
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before the disease spreads further.  The ability to rapidly share the results of positive and 
negative tests can revolutionize the manner in which infectious diseases are managed.  
Therefore, it is of paramount importance for the test to be performed at the same location 
as the patient, so action can be taken on the same day the sample is gathered. 
Taking advantage of the fact that bacteria and viruses have distinct genetic 
components that are represented by unique nucleic acid sequences, the most commonly 
used laboratory analysis technique for diagnosis of infectious disease is the polymerase 
chain reaction (PCR) [46-48].  PCR enables sequence-specific concentration amplification 
of infectious disease DNA through a series of thermally cycled chemical reactions between 
a set of enzymes, a prepared test sample (DNA extracted from a pathogen-containing 
bodily fluid), and disease-specific “primer” molecules.  PCR primers for detection of every 
common human and animal infectious disease have been identified, and may be 
inexpensively synthesized through readily available commercial sources. Conventional 
PCR amplification requires expensive laboratory-based instruments that are operated by 
technicians and housed in central facilities, although there have been strong efforts aimed 
at miniaturization of PCR for translation closer to the point-of-care through the engineering 
of systems integrated into a small chip or cartridge. Many of these efforts have been aimed 
at accelerating the thermal cycling process through reduction in the liquid volume  [49-51] , 
while others have explored various modalities for sensing the presence of the amplified 
product using biosensors [52-53].  Due to the cost and complexity of implementing thermal 
cycling (generally between 95°C (denaturation), 72°C (extension), and 68°C (annealing) 
with ~30-40 cycles), various isothermal nucleic acid amplification methods have been 
proposed and demonstrated with comparable sensitivity to PCR [54-56], but with a 
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requirement to more fully customize and validate the primer sequences. Of these, loop-
mediated isothermal amplification (LAMP) has emerged as the favored approach for 
simple and portable applications [57-59].   
An important prerequisite for the widespread adoption of point-of-care tests is the 
availability of detection instruments that are inexpensive, portable, and able to share data 
wirelessly over the internet. Due to the rapid development of computational, 
communication, and sensing capabilities of smartphones since the introduction of the 
iPhone in 2007, these devices have become similar to personal computers with integrated 
cameras, geolocation capabilities, and access to the internet.  Since 2011, over 478 million 
smartphones are sold annually, with that number expected to double in the next 4 years 
[60], making them a nearly ubiquitous tool that can be adapted to performing POC tests. 
Recent examples include attachments that enable smartphones to serve as stethoscopes [61], 
ultrasound probes [62], microscopes [63], fluorescent microscopes [64, 65], label-free 
biosensor detection instruments [66, 67], fluorimeters [27], and ELISA assay readers [68]. 
Portable detection systems for infectious disease are already recognized as a likely 
extension of mobile technology [69-71], although to date there is no existing PCR or 
LAMP mobile sensing platform that is integrated with a smartphone and a smart service 
system for reporting and sharing results with a network of users. 
In this work, we have developed a smartphone-based portable detection instrument 
to perform LAMP-based analysis for the diagnosis of equine respiratory infectious diseases. 
We initially focus specifically upon equine respiratory infections due to their economic 
importance to the horse racing industry, similarity to the tests that would have an impact 
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upon the food animal industry, and the strong need for a service system that can inform 
networks of field veterinarians. Our work involves the development of a microfluidic 
approach for identifying the presence of specific nucleic acid sequences from the pathogens 
of equine respiratory infections using a portable detection system integrated as a disposable 
cartridge that can be read by a conventional smartphone. Capable of simultaneously 
performing 10 parallel isothermal amplifications with 2 for experimental controls and 8 for 
pathogen detection assays, the system can detect more than one pathogen with a single test 
protocol, and interface with a smartphone app that communicates with a cloud-based 
service for the immediate reporting of the location, time, identity, and results (positive and 
negative) of the detection. In this work, four LAMP-based assays have been developed for 
the detection of four important equine respiratory infectious pathogens including 
Streptococcus Equi (S. Equi), Streptococcus Zooepidemicus (S. Zoo), and equine 
herpesvirus type 1 and 4 (EHV-1, 4). The smartphone-based detection demonstrates the 
same level of limit of detection (LOD) and sensitivity as compared to the LAMP reactions 
performed on commercially available thermocyclers, and is capable of identifying the 
pathogens for both single-infection and co-infection scenarios. To our knowledge, a 
smartphone-based nucleic acid testing approach for the diagnosis of veterinary infectious 
diseases has not been reported in previous literature.    
 
2.2. Materials and methods 
2.2.1. Chip substrate fabrication 
To perform multiplex LAMP-based detection of pathogen-specific nucleic acids, a 
 40 
 
silicon-based microfluidic chip with 10 parallel flow channels and a shared sample inlet is 
created. The chip is the size (25 mm × 15mm) of a standard SIM card. Flow channel 
dimensions are 10 mm in length, 500 µm in width and 200 µm in depth, representing a 
volume of 1µL each. The inlet of the chip is a 4 mm diameter circle with the boundary 
connected to the follow channels through ten connectors. Two square markers at the 
opposite end of the chip are used for the position alignment in the fabrication process and 
also in the final image analysis step. The fabrication process for the microfluidic chip is 
illustrated in Figure 2.1(a), while the real photo of the chip is shown in Figure 2.1(b). A 4-
inch <100> silicon wafer (University Wafer, South Boston, MA) with one side polished is 
thoroughly cleaned and used as the substrate in the photolithography process. Positive 
photoresist SPR 220 (MicroChem, Newton, MA) is spin-coated on the polished side of the 
wafer to form a 4.5 µm covering layer, followed by the soft-bake at 60 °C for 2 min and 
110 °C for 1 minute. The photoresist is then exposed with an i-line (365 nm) mask aligner 
(EVG 620) with an expose dose of 180 J/cm2. The exposed regions of the photoresist with 
the outline of the microfluidic pattern are subsequently removed by immersing the wafer 
in AZ developer diluted 1:4 with deionized (DI) water for about 4 minutes. The photoresist 
in the unexposed regions is solidified though a hard-bake at 110 °C for 1 minute. For the 
anisotropic etching of the silicon substrate, a Bosch process with alternating steps of SF6/O2 
etching and C4F8 passivation is used to create a 200 µm deep trench in an inductively 
coupled plasma reactive ion etcher (ICPRIE). The scanning electron micrograph (SEM) in 
Figure 2.1(c) shows the vertical sidewalls of the etched channels. After the Bosch process, 
the remaining photoresist was stripped with acetone and O2 plasma cleaning, leaving the 
bare silicon exposed. Because bare silicon has been reported to have inhibitory effects on 
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nucleic acid amplification due to absorption of polymerase [48], the wafer was thermally 
oxidized in a furnace (1150 °C) for 2 hours to grow 200 nm SiO2. The final fabrication step 
of the chip fabrication is to dice the wafer into 11 individual chips. 
 
2.2.2. Chip preparation and sealing  
Before the experiment, all the microfluidic chips are stored under vacuum in a 
desiccator after being thoroughly cleaned with piranha solution, a mixture of 98% sulfuric 
acid (H2SO4) and 30% hydrogen peroxide (H2O2) at the ratio of 3:1, rinsed with DI water 
and then dried with nitrogen gas. For the on-chip experiments, an adhesive membrane and 
a glass coverslip are used to prevent the evaporation of the reaction solution in the flow 
channels during heating at 65 °C. The chip is covered with a transparent double-sided 
adhesive (DSA) (ARseal™ 90880; Adhesives Research, Glen Rock, PA) with laser-
machined holes after the deposition of primers into the channels. The holes are cut to match 
the position of inlets and ends of the channels at the substrate, to allow for the injection of 
LAMP reaction solutions. The DSA forms a barrier to evaporation or cross-contamination, 
and it is compatible with the reagents used in the amplification reaction. After the reaction 
solution is injected into the channels, the chip is sealed with a glass coverslip (GOLD 
SEAL®  63760-01; Electron Microscopy Sciences, Hatfield, PA) by peeling off the top 
covering layer of DSA and binding it with the coverslip. The binding is robust enough to 
effectively prevent the entrance of air into the flow channels from the surrounding 
environment. 
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2.2.3. Primer deposition  
The primers are uniformly deposited onto the surfaces of the flow channels before 
sample loading through the pipette injection at the endpoint of each channel. Figure 2.1(d) 
shows the deposition plan for the four types of primers and two experiment controls. 
Channel 1 works as the positive control as the deposited molecules are a mixture of both 
the primer set and template DNAs for S. Zoo assay, while channel 2 is used as the negative 
control as no primers are deposited on its surface. Meanwhile, the other eight channels are 
divided into four groups to allow for the deposition of four types of primer sets used in this 
work, with channels 3 and 4 deposited with primers for S. Equi assay, channels 5 and 6 
deposited with primers for S. Zoo assay, channels 7 and 8 deposited with primers for EHV-
1 assay, and channels 9 and 10 deposited with primers for EHV-4 assay. The primer 
solutions injected at the eight channels are prepared in the same manner, through a direct 
20-fold dilution of the corresponding primer solution (originally at 55µM) in nuclease-free 
water, giving a final primer concentration of 2.75 µM. For the solution injected in the 
positive control channel, 1 µL of the S. Zoo DNA sample solution at the concentration of 
5×106 copies/mL is mixed with 1 µL of 20 times diluted 55µM S. Zoo primer solution to 
make a 2 µL final solution. After the solutions are prepared, a volume of 1 µL of each 
solution is taken by a pipette and injected into the flow channels from the end of each 
channel. The solution can flow along the etched trench reaching the other end of the flow 
channel without entering the connector part and the inlet. Because of the small volumes, 
all the primers can be completely dry on the channel surface at room temperature within a 
few minutes. The primer deposition process can also be automated using printing 
technology. 
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2.2.4. LAMP assay development  
We have developed four specific LAMP assays to show the feasibility of our 
smartphone-integrated instrument in multiplex pathogen detection. 
S. Equi (ATCC®  9528™; ATCC, Manassas, VA), S. Zoo (ATCC®  39920™; ATCC, 
Manassas, VA), EHV-1 (040-EDV; USDA, Champaign, IL), and EHV-4 (044-EDV; 
USDA, Champaign, IL) are chosen as the pathogens of interest due to their widespread 
virulence among horse populations. The S. Equi and S. Zoo bacteria are received in 
lyophilized form and are propagated in bovine-brain heart infusion medium (Sigma-
Aldrich, St. Louis, MO) for a period of 16 hours to obtain a carrying concentration of 1×108  
colony forming units (CFU)/mL. Glycerol stocks are prepared from this concentration and 
are stored at -80 °C until experiments. The EHV-1 and EHV-4 stock is aliquoted into 
smaller volumes and also stored at -80 °C until experiments. DNA from all the pathogens 
is extracted via a standard heat-lysing protocol [72]. The extracted DNA is quantified using 
PCR standard curves that are established using synthetic targets.  
A 25 μL LAMP reaction mix contains the following: 3.5 μL of 10 mM dNTPs (New 
England Biolabs, Ipswich, MA), 2.5 μL of 10X Isothermal Amplification Buffer (New 
England Biolabs), 2 μL of 5 M Betaine (Sigma-Aldrich), 1.5 μL of 100 mM Magnesium 
Sulfate Solution (New England Biolabs), 2 μL of primer mix, 2 μL of 8000 units/mL Bst 
2.0 Warmstart DNA Polymerase (New England Biolabs), 1.25 μL of 20X Evagreen Dye 
(Biotium, Fremont, CA), 2.25 μL of DEPC-treated water (Invitrogen, Carlsbad, CA), and 
8 μL of the template DNA (New England Biolabs). The LAMP reactions are first carried 
out on a benchtop thermocycler (Mastercycler®  RealPlex; Eppendorf, Hamburg, Germany) 
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at 65 °C for 40 minutes and are terminated by heating at 85 °C for 5 minutes. The 25 μL 
reaction mix is divided into three equal parts (8 μL) for triplicate repetition. Ten-fold serial 
dilutions of the extracted DNA are carried out in DEPC-treated water to determine the 
working range of our LAMP assays.  
Novel LAMP primers are designed for the assays of S. Equi and S. Zoo targeting 
the seM and sorD genes respectively. The target sequence for S. Equi is obtained from the 
NCBI database using GenBank AJ249868.1 and U73162.1. The target sequence for S.Zoo 
is also obtained from the NCBI database using GenBank CP002904.1, NC_011134.1, and 
FM204884.1. LAMP primers are designed using the PrimerExplorer V4 
(https://primerexplorer.jp/e/). LAMP primers for EHV-1 and EHV-4 are borrowed from 
the works of Nemoto et al. [73]. All LAMP primers are synthesized by Integrated DNA 
Technologies (Coralville, IA) and are listed in Table 2.1. Briefly, each primer mix consists 
of 0.2 μM of F3 and B3, 1.6 μM of FIP and BIP, and 0.8 μM of Loop F and Loop B primers. 
 
2.2.5. Smartphone-based instrument  
The smartphone-based instrument to measure the fluorescent emission from the on-
chip LAMP reactions is shown in Figure 2.2. The system consists of a smartphone (Nexus 
6; Motorola, Chicago, IL) and a lightweight 3D-printed cradle that contains the optical and 
electrical components to excite and collect fluorescence signals at a constant temperature. 
The top part of the cradle interfaces with the existing camera module (13 megapixels, pixel 
size of 1.4 µm) of the phone. The cradle helps align the smartphone camera with the 
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internal optomechanical components, and also serves as a dark chamber for the 
fluorescence detection by blocking the external light. When the mobile phone is slid into 
the slot at the top of the cradle, the rear-facing camera is aligned on top of an opening 
window (dia. = 30 mm) that is formed by a 525 nm long pass filter (#84-744; Edmund 
Optics, Barrington, NJ) and a 12.5X macro lens (TECHO) in a row. The long pass filter is 
selected according to the emission wavelength of the fluorescent dye used in the LAMP 
assay. The macro lens placed in front of the camera facilitates close-up photography of the 
chip, allowing the reduction of the distance between the camera and the chip to 50 mm 
while keeping the field of view as large as 24 × 24 mm with a barrel distortion negligible. 
A light source module composed of eight 485 nm blue light-emitting diodes (XPEBBL; 
Cree, Inc., Durham, NC) and four 490 nm short pass filters (ZVS0510; Asahi Spectra, 
Torrance, CA) that cover each pair of LEDs is installed at the upper corners of the cradle 
to provide the excitation light that does not overlap with the dominant fluorescence 
wavelengths to detect. The LEDs are mounted on a custom-built printed circuit board (PCB) 
and arranged with square symmetry to support uniform illumination over the whole chip 
area. The light source module is powered by two AAA batteries and operated using an 
on/off control switch. A positive temperature coefficient (PTC) heater (12V-80˚C; Uxcell, 
Hong Kong, China) is placed beneath the chip, keeping it at a temperature around 65 ˚C 
without an additional temperature controller. The PTC heater is made from specific 
ceramic materials that have a highly nonlinear thermal response and a positive thermal 
coefficient of resistance. When the temperature of the heater exceeds a composition-
dependent threshold temperature, the electrical resistance increases resulting in decreased 
heat output to set the temperature at a predefined limit. The installed PTC heater is powered 
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by a standard 9 V battery to set the temperature of the microfluidic chip around 64~ 66 ˚C 
during the measurements and operated using an on/off control switch. The overall 
dimensions of the cradle are ~ 90 × 70 × 95 mm3. 
 
2.2.6. Fluorescence microscopy  
Fluorescence microscopy is used to capture the real-time images of the on-chip 
LAMP reactions under a Nikon Eclipse FN1 fluorescence microscope with a 2X objective 
and a Nikon 96311 B-2E/C FITC fluorescence filter. The sealed microfluidic is placed on 
an INSTECT mK1000 heating stage that is located under the microscope objective. The 
field-of-view of the objective is large enough to measure the fluorescence output from the 
six channels of the microfluidic chip at the same time. NIS Elements software provided by 
Nikon is programmed to capture fluorescence images every 1 minute with the setting of 
9.6X gain and 1 s exposure time. 
 
2.2.7. Image analysis and app development  
The endpoint images of the on-chip reactions captured by the smartphone-based 
instruments are in the format of JPG, and they can be exported out of the smartphone to be 
analyzed with Matlab or analyzed through a custom-built Android app. The Matlab 
analysis starts with the importing of the image as a 3120 × 4160 × 3 matrix. The first two 
dimensions represent the size of the image, and the last dimension provides a 24-bit RGB 
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(red, green, blue) color space. Each of the RGB intensity components of each pixel is stored 
as an 8-bit unsigned integer ranging from 0 to 255. Since the fluorescence light emitted 
from the microfluidic chip is in green color centered at 530 nm wavelength, only the G 
channel intensity is used in the following image processing. The spatial location for each 
of the 10 lanes can be recognized through a boundary detection method. Within each lane, 
which usually covers a range of 40 × 700 pixels, the average and standard deviation (STD) 
of all the pixel intensities are calculated. The average intensity obtained from lane 2, which 
is the negative control, indicates the background intensity of the fluorescence measurement. 
For this reason, it is used as the baseline and subtracted while computing the final output 
intensity of all the other lanes.  The Android app process the images in a similar manner. 
After the images are captured by the smartphone, a boundary detection algorithm is applied 
to help find the locations of the ten lanes, as shown by Figure 2.3. Then the average value 
of each lane is computed and shown on the screen.  
The series of images measured in the real-time measurement is recorded by the 
fluorescence microscope and saved as grayscale TIFF files. These images are imported into 
Matlab as a 1024 × 1280 matrix of 16-bit unsigned integers (range: 0-65535). Limited by 
the field-of-view of the objective, six of the ten lanes can be monitored and showed up on 
the images. The average pixel intensities in the regions of each lane are calculated and 
recorded. Since the image frames are taken at the interval of 1 min, the variation of the 
average intensities of the six lanes can be plotted versus time to make the amplification 
curves. 
 
 48 
 
2.3. Results and discussion 
The overall goal of this research is to provide a mobile, simple, rapid, and 
inexpensive approach for the multiplex detection of the pathogens of equine respiratory 
infectious diseases using LAMP assays and to establish a network system for the 
epidemiological tracking of veterinary infectious diseases via smartphones. Our approach 
involves the development of a ten-channel microfluidic chip, multiple pathogen-specific 
LAMP assays, a smartphone-based detection instrument to perform fluorescence 
microscopy, and an Android app for image processing and data sharing. The microfluidic 
chip is made of oxidized silicon and is the same size as a standard SIM card. It has a single 
inlet for sample loading and ten parallel flow channels for the multiplex on-chip LAMP 
reactions. LAMP assays are developed for the detection of two bacterial pathogens and two 
viral pathogens of equine respiratory infections: S. Equi, S. Zoo, EHV-1 and EHV-4. The 
intercalating dye (EvaGreen) in the reaction reagents can be used to monitor the DNA 
amplification process by measuring the green fluorescence emission. The dye becomes 
significantly brighter when bound to double-stranded DNA (dsDNA), but remains dark 
when unbound in solution.  
For simultaneous measurement of the presence of multiple pathogens with a single 
protocol, the primer sets of the four assays are pre-deposited onto the surface of the flow 
channels before sample loading, with each type of primer occupying two channels. The 
remaining two channels are used as the positive and negative controls of the on-chip 
reactions to set upper and lower bounds for the fluorescent reading. In the positive control 
channel, the primers and the corresponding template DNAs are mixed and then deposited 
 49 
 
together on the channel surface. While in the negative control channel, no primers are 
deposited. Therefore, the positive control is expected to generate high-intensity green 
fluorescence independent of the DNA sample loaded into the microfluidic chip so as to 
indicate the validity of the on-chip reactions, and the negative control should be dark on 
the fluorescence image since no amplification can happen without primers. The primer 
solution is dried at room temperature within a few minutes leaving the primer molecules 
uniformly distributed on the surface of microfluidic channels.  
After the primer deposition, the chip is covered with a transparent, biocompatible 
and anti-evaporation DSA layer with the holes of inlet and outlets (the endpoint of each 
channel) that are aligned with the substrate silicon chip. In order to ensure device 
cleanliness, non-contact laser cutting is used to cut the holes on the DSA. The samples 
tested in the experiments are DNA extracted from the four pathogens via a standard 
protocol. For each on-chip experiment, a volume of 15 µL LAMP reaction solution is 
prepared, injected through a pipette at the inlet of the chip, and immediately flows inside 
to fill all the microfluidic channels. To prevent the evaporation during the LAMP 
incubation at 65 °C, the top layer of DSA is peeled off and a thin transparent coverslip the 
same size as the DSA is used to seal the whole chip. Such room temperature sealing of the 
chip is desired so as not to promote the binding of the primers on the chip surface. All the 
materials used in the microfluidic chip have low background fluorescence, thereby 
ensuring high-quality imaging of the fluorescence signal during measurement.  
A smartphone-based instrument is developed to perform endpoint measurement of 
the on-chip LAMP reactions by packaging the optical components in the form of a custom 
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cradle and utilizing the back-facing camera of a smartphone to capture the fluorescence 
images. Produced from plastic by 3D printing, the cradle housing incorporates a circuit 
board that integrates eight LEDs for illumination, optical filters, battery power, a macro 
lens and a heating block for the heating of the chip during measurement. Such mobile 
platform can provide sufficient detection sensitivity for fluorescence microscopy that is 
equivalent to much larger and more expensive laboratory instruments.  
The microfluidic chip is loaded by a plastic card and inserted into the cradle after 
the activation of the LAMP reactions through a single temperature incubation at 65 ºC. The 
card is in the shape of a credit card can provide a surface upon which assay information 
may be printed. To record the fluorescence intensity from each channel of the microfluidic 
chip, an app in the smartphone is developed to capture the image, recognize the channel 
locations and calculate the average intensity of each lane. The fluorescence images 
obtained during the experiments can be shared to a cloud-based data management center 
for remote access of the detection results and for the establishment a reporting system for 
infectious diseases.  
To compare the imaging capabilities of the smartphone-based system with the 
standard laboratory imaging equipment, both the fluorescence microscope and the 
smartphone are used to characterize the on-chip reactions. Two types of integrated 
experiments are performed; one is for the identification of a single positive pathogen 
among multiple negatives, and the other is the identification of two randomly selected 
pathogens, in order to demonstrate the capability for the detection of co-infection. 
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2.3.1. Off-chip characterization of the LAMP assay  
Figure 2.4 shows the off-chip LAMP assay characterization of S. Equi, S. Zoo, 
EHV-1, and EHV-4 using purified DNA templates. LOD of the off-chip assays are 
determined through the characterization experiments. The lower LODs are 5×104 
copies/mL for S. Equi, 5×103 copies/mL for S. Zoo and EHV-1, and 1×103 copies/mL for 
EHV-4. Only 2 out of the 3 replicates amplify in the 5×103 copies/mL test for S. Zoo assay.  
As a comparison, the PCR assays for all four pathogens demonstrate a detection limit of 
1×105 copies/mL. To test the specificity of our LAMP assays, we test each of the four 
template DNA samples against different primer sets. Specific template-primer 
amplification is observed in all the four cases. The results are summarized in Figure 2.5 
and Table 2.2. Our off-chip LAMP assays have shown appreciable sensitivity with LOD 
higher than that of PCR, and are specific for each pathogen type, thereby validating their 
use in the on-chip multiplexing experiments as described later. 
 
2.3.2. On-chip characterization of the LAMP assay  
Figure 2.6 and 2.7 show the on-chip characterization of the S. Zoo LAMP assay. A 
fluorescence microscope is used to monitor the reactions within six channels in real-time 
lasting for 60 minutes. The characterization starts from a negative control test as shown in 
Figure 2.6(a), where DI water is used as the sample to detect and no S. Zoo DNAs are 
added into the reaction reagents. No amplification occurs within 60 minutes. It is the same 
case for the reactions with low DNA concentration at 5×103 copies/mL (Figure 2.6(b)). 
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When the DNA concentration increases to 5×104 copies/mL (Figure 2.6(c)), all 6 lanes are 
observed to start amplification reactions within 60 minutes, and 3 of the 6 reach the plateau 
stage at 30 minutes. Therefore, the LOD for on-chip S. Zoo LAMP assay is 5×104 
copies/mL. As the DNA concentration continues increasing to 5×103 and 5×104 copies/mL, 
every lane shows uniform amplification within 20 minutes, as shown by Figure 2.6(d,e). 
The on-chip characterization is also performed for the S. Equi, EHV-1 and EHV-4 assays 
(Figure 2.8-2.10), which shows the LODs for the three assays are 5×104 copies/mL, 5×103 
copies/mL and 5×103 copies/mL, respectively. The LODs are the same order as that 
obtained from the off-chip characterization.  
 
2.3.3. Integrated experiment for the detection of one target pathogen  
Integrated experiments are designed to demonstrate the full capacity of this 
approach for the mobile identification and detection of viral and bacterial pathogens. Four 
types of primers used in the four developed LAMP assays and the positive control mixture 
are deposited on the microfluidic channels according to the method described in “primer 
deposition”. When pathogen-specific DNA templates are present in the sample injected 
into the microfluidic chip, the corresponding two channels as well as the positive control 
channels are supposed to be bright and emit green fluorescent light while the other channels 
should be dark. By measuring the fluorescence output from each channel using the 
smartphone-based instrument and the app, detection results can be quickly analyzed and 
displayed.  
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Figure 2.11 shows the results for the four integrated experiments performed for the 
detection of each of the four types of pathogens. For the experiment shown in Figure 
2.11(a), the sample loaded into the chip contains 5×107 copies/mL S. Equi DNAs. As seen 
by the fluorescence image, lanes 3 and 4, where the S. Equi primers are located, become 
as bright as the positive control (lane 1).  To quantitatively analyze the fluorescence image, 
the average intensities of the ten lanes, as processed in the method described in section 
2.2.7, are calculated as 53.6, 0, 58.6, 58.1, 9.3, 3.4, 15.6, 19.2, 13.6, and 0.7. The threshold 
value is set at half the value of the positive control, or 26.8 (= 53.6/2). As shown in the bar 
graph in Figure 2.11(a), only the intensities of lanes 3 and 4 are significantly higher than 
the threshold, while the intensities of all the other lanes are well below the threshold. The 
variations in the intensities of the negative lanes for lanes 5 to 10 are due to the difference 
in the background intensity of LAMP assays and the variation in LED illumination. Similar 
experiments are done with the other three types of pathogens. In Figure 2.11(b), the 
concentration of the injected S. Zoo DNAs is 5×106 copies/mL. In accord with the 
prediction, after the on-chip reactions, lanes 5 and 6 stand out clearly in terms of 
fluorescence intensity. The average G-channel signals for lanes 1 to 10 are: 68.4, 0, 1.4, 
1.4, 53.3, 47.0, 3.6, -3.2, -9.1, and 6.6. Figure 2.11(c,d) show the detection results for the 
two viral pathogens, EHV-1 and EHV-4. Both experiments show clear evidence that the 
presence of specific pathogens can be identified among the panel of suspected pathogens 
by identifying the bright lanes on the fluorescence images. The concentration for the 
injected EHV-1 and EHV-4 DNAs are 5×106 copies/mL and 2×106 copies/mL, respectively. 
When the sample to detect is EHV-1 DNAs, the lanes 7 and 8 are bright, while the last two 
lanes become bright when the sample injected is EHV-4 DNAs. The output intensity values 
 54 
 
from each lane are 43.7, 0, 1.3, -0.9, -1.3, -1.6, 35.2, 35.6, 6.7, and 12.9 for EHV-1 
experiment, and 56.9, 0, -0.2, -0.3, 0.2, -1, 17.9, 16.3, 42.2, and 47.8 for EHV-4 experiment. 
In both cases, only the lanes where the specific primers are deposited can generate 
fluorescence intensity that is higher than the threshold value. All the captured images are 
saved to an online cloud storage center and can be remotely accessed by the system users. 
 
2.3.4. Integrated experiment for the detection of co-infection 
Due to the increased risks brought by co-infections and the fact that the same 
clinical symptom can be caused by infections from several agents, a POC test which can 
simultaneously detect multiple pathogens from a single specimen is highly desirable. To 
further demonstrate the effectiveness and robustness of the mobile pathogen detection 
platform, we also apply the system to the detection of the sample where two pathogens co-
exist. The sample prepared for this experiment contains 4×104 copies/mL EHV-1 DNAs 
and 3.2×105 copies/mL EHV-4 DNAs, while the microfluidic chip is prepared in the same 
way as above. The detection results are depicted in Figure 2.12. As shown by the 
fluorescence image captured by the smartphone, the high-intensity lanes can be clearly 
identified as lane 1, the positive control, lanes 7 and 8, which indicate the existence of 
EHV-1, as well as lanes 9 and 10, which indicate the existence of EHV-4. Quantitatively, 
the average intensities of each lane are 56.91, 0, 10.29, 9.47, 15.11, 13.73, 46.75, 46.39, 
48.99, 52.08. The lanes corresponding to the positive pathogens are significantly brighter 
than the others. This result is in accordance with the types of pathogen DNAs that exist in 
the tested sample. The two pathogens here are randomly selected, and detection of the 
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combination of any other types of pathogen could also be performed with the developed 
platform. 
 
2.4. Conclusion 
We demonstrate a smart service system for the detection and identification of viral 
and bacterial pathogens of infectious diseases using a mobile instrument. The system 
utilizes a microfluidic approach for performing LAMP-based isothermal amplification of 
a multiplexed array of 1 to 10 pathogen-specific nucleic acid sequences, and uses a hand-
held cradle that interfaces with the rear-facing camera of a conventional smartphone to 
capture the fluorescence images. The captured images are processed by a smartphone app 
and shared to a cloud-based center for the reporting and remote access of the detection 
results. Four assays have been developed for the detection of the pathogens of equine 
respiratory infectious diseases, including S. Equi, S. Zoo, EHV-1 and EHV-4. The system 
demonstrates the capacity of multiplex pathogen detection at the same time to meet the 
challenges brought by co-infections. The detection system enables rapid determination and 
reporting of instances of infectious disease that can inform treatment and quarantine 
responses that are currently not possible with tests performed at central laboratory facilities. 
Especially, cost reduction under the scenario of the POC test is achieved by performing 
data acquisition, analysis, and broadcast using a smartphone instead of customized 
hardware. Also, the use of preloaded microfluidic cartridges minimizes hands-on labor or 
required training. We believe this approach provides a mobile, simple and inexpensive 
capability for clinicians to perform infectious disease diagnostics, and it represents a 
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significant stride towards a practical solution to infectious disease diagnostics at resource-
limited settings.  
 
2.5. Figures 
 
Figure 2.1. Ten-flow channel microfluidic chip for multiplex LAMP detection. (a) 
Schematic diagram for the fabrication process of the microfluidic chip. (b) Photo of a 
fabricated chip taken with a quarter coin. (c) Scanning electron microscope (SEM) of the 
cross-section of the microfluidic channels. (d) Primer deposition plan for the on-chip 
reactions.  
 
 
 57 
 
Figure 2.2. Smartphone-based instrument. (a) Schematic diagram to show the internal 
structure of the cradle that integrates optical and electrical components used for 
fluorescence microscope. A microfluidic chip is loaded inside the cradle on top of a PTC 
heater to maintain a constant ~ 65 °C temperature. (b) Photo of the smartphone-based 
instrument taken with the smartphone and chip card.  
 
 
 
Figure 2.3. Smartphone app developed for the recognition of the microfluidic channels 
and the calculation the of the G-channel intensity of each channel. 
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Figure 2.4. Off-chip characterization of the four LAMP assays developed for the 
detection of equine respiratory infection pathogens. The amplification curves and 
threshold time versus concentration relationship are plotted for (a) S. Equi assay, (b) S. 
Zoo assay, (c) EHV-1 assay, and (d) EHV-4 assay. 
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Figure 2.5. Off-chip characterization of assay specificity. The real-time reaction curves 
of the (a) S. Equi DNA, (b) S. Zoo DNA, (c) EHV-1 DNA and (d) EHV-4 DNA with all 
the four primers and negative control. 
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Figure 2.6. On-chip characterization of the S. Zoo assay. The negative control (a) and 
low DNA concentration test (b) show no amplification within 60 minutes. (c) The limit-of-
detection of on-chip reaction is 5×104 copies/mL. The amplification reactions begin within 
15 minutes for the high concentration tests at (d) 5×105 copies/mL and (e) 5×106 copies/mL. 
 
 
Figure 2.7. Real-time measurement of the on-chip reactions when sample contains S. 
Zoo DNAs is loaded into the microfluidic chip. The images are captured every 1 minute 
using the fluorescence microscope. The images captured at (a) 5 minutes, (b) 10 minutes, 
(c) 15 minutes, and (d) 20 minutes are shown here. Only the positive control and channels 
deposited with S. Zoo primers become bright.  
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Figure 2.8. On-chip characterization of S. Equi assay. The limit of detection for the on-
chip reaction is 5×104 copies/mL. 
 
 
Figure 2.9. On-chip characterization of EHV-1 assay. The limit of detection for the on-
chip reaction is 5×103 copies/mL. 
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Figure 2.10. On-chip characterization of EHV-4 assay. The limit of detection for the 
on-chip reaction is 5×103 copies/mL. 
 
 
Figure 2.11. Integrated experiments for the identification of single pathogen. 
Smartphone-captured images and intensities from each lane are shown for (a) S. Equi, (b) 
S. Zoo, (c) EHV-1, and (d) EHV-4. The LAMP reactions only happen in positive control 
channel and the channels deposited with the specific primers. The existence of specific 
pathogen can be identified by the brightness of the lanes on the fluorescence images.  
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Figure 2.12. Integrated experiment for the detection of co-infection. The sample 
detected here contains both the EHV-1 and EHV-4 DNA templates. Lane 1 (the positive 
control), lanes 7 and 8 (the lanes for EHV-1 detection), and lanes 9 and 10 (the lanes for 
EHV-4 detection) become bright after the on-chip reactions.  
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2.6. Tables 
Table 2.1. Sequence of primers used in the LAMP assays 
 
 
Pathogens Assay Sequences Sequence 
Streptococcus 
Equi 
 
LAMP 
F3: AAA ACT AAG TGC CGG TGC2 
B3: AAA ACT AAG TGC CGG TGC2 
FIP: TAC GAC TAA CCT CAG AGT TCG CTA TCA 
GTA TTA GTT GCA ACA AGT G 
BIP: CGA CTC CAA GAT TAT CGC GTG ATT GAA 
CTT TTT GGG CTG ATG A 
Loop F: ACA GTT GTC CCT CCC AAC A 
Loop B: GCG ATA TAG CCA TAA GTG GAG ATG 
PCR 
F: CGG ATA CGG TGA TGT TAA AGA 
R: TTC CTT CCT CAA AGC CAG A 
Streptococcus 
Zooepidemicus 
LAMP 
F3: AAA GAC CCT CAT GGG AAA T 
B3: CCT TAG TTG CCG CAT AGG 
FIP: CCT GAC TAA CCA AAT ATA AGC CCT TGA 
GCT GGA CGA TAA GAC CT 
BIP: TGT TGG ACG TAT TTT GGT TGC TCT TCT GAG 
CCT TCT AAA CCT G 
Loop B: GGT GTC ATT ATT AAC ATG GCC TCT 
PCR 
F: CAG CAT TCC TGC TGA CAT TCG TCA GG 
R: CTG ACC AGC CTT ATT CAC AAC CAG CC 
Equine 
Herpesvirus 4 
 
LAMP 
F3: CAA GAC GTA ACA ACG GGA GT 
B3: CGC AAG TAA CGG CGA TGA 
FIP: CGC TCT CCG TTT TCT TCC GAC AAG CCA CCC 
AGG ATT AGT CAA 
BIP: TTA CCC GGA CGG CCT TCC AAC GGG CAT 
GTC CTC AAC AA 
Loop F: GCC TGC TAC TCC GCA TG 
Loop B: AGC GTT GTA TAT GAT GCA TCC CCT 
PCR 
F: GAC CTC TCC GTT CAC CCA AG 
R: TCC GTT TTC TTC CGA CAG GG 
Equine 
Herpesvirus 1 
 
LAMP 
F3: GGC ATT TAC GTG TGG TCC TT 
B3: TCG CGG GCA TTT TTG TAC C 
FIP: GTC CAG CAA CGG TGC GTT GTG GCA CGC 
TCG TTA ACA GT 
BIP: CGA GCC TGA AGG GGG AAA ACT GGA GCT 
GTG TGG AAA GTA GC 
Loop F: AGG TTG AGA CGG TAA CGC TG 
Loop B: CAC GTG CGT CGT CGC AA 
PCR 
F: GCG CCA GCT GTT TAA CCT TC 
R: CGG GCA TTT TTG TAC CAC CG 
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Table 2.2. Summary of the specificity of the four LAMP assays 
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CHAPTER 3 
MULTIPLEXED DETECTION OF ZIKA, DENGUE, AND 
CHIKUNGUNYA FROM WHOLE BLOOD                                           
AT THE POINT-OF-CARE 
 
3.1. Introduction 
A member of the family Flaviviridae, genus Flavivirus, zika virus appeared in the 
international spotlight in late 2015 as evidence emerged of a possible link between an 
epidemic affecting Brazil and increased rates of microcephaly in newborns [74]. Like other 
febrile virus infections such as dengue and chikungunya, zika virus is transmitted by the 
bite of infected Aedes aegypti and Aedes albopictus mosquitos [75]. Human-to-human 
spread is also well documented, including in utero transmission from mother to fetus, 
sexual transmission, and in one unusual case, non-sexual spread through close contact with 
an individual of high viremia, likely sweat or tears [76]. While most zika virus infections 
are asymptomatic, those who manifest the disease typically exhibit non-specific symptoms 
including to varying degrees: rash, fever, arthralgia, conjunctivitis, myalgia, headache, 
retro-orbital pain, edema, and vomiting [77, 78], many of which overlap significantly with 
acute dengue and chikungunya virus infections. Moreover, zika virus infection has been 
reported to cause Guillain-Barré syndrome, a neurological complication involving 
progressive paralysis capable of resulting in respiratory failure and death [77, 78]. 
The non-specific presentation of zika virus symptoms and shared vectors with 
febrile diseases such as dengue and chikungunya present a significant diagnostic challenge: 
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no combination of symptoms is adequately unique to make a clinical diagnosis of zika virus. 
The problem is aggravated in resource-limited regions where all the three virus infections 
are endemic resulting in the need for specific diagnosis for informed clinical intervention, 
better patient management, and epidemiological surveillance [79, 80]. This creates a need 
for low-cost and portable platforms that can provide fast, accurate, and multiplexed 
diagnosis of all such diseases at the point-of-care. Current gold standard in zika virus 
detection involves nucleic acid detection, real time PCR (RT-PCR), and antibody serology 
with an immunoassay [77]. A major challenge, however, is cross-reactivity of antibodies 
in individuals with prior dengue infection, rendering serology an imperfect approach that 
can be difficult to interpret in such scenarios. RT-PCR, meanwhile, remains an expensive 
and highly-technical method with long testing hours making it incompatible in regions with 
poor healthcare infrastructure. 
Loop-mediated isothermal amplification emerged within the last two decades as an 
alternative to PCR for nucleic acid amplification [81]. This method has been leveraged for 
higher specificity of its 4-6 primer systems, single-temperature incubation, and increased 
resistance of the Bst polymerase to inhibitors that prevent PCR. LAMP and RT-LAMP 
have been employed in the literature for a variety of nucleic acid detection applications 
including point-of-care platforms [82-84], and, in just a few recent reports, zika virus 
detection [85-87]. Few, however, have leveraged the robustness of the LAMP polymerase 
for detection of pathogens directly in unprocessed whole blood [88-90]. The detection of 
zika virus is confounded by the short window of detection of the virus in serum, urine, and 
saliva [91, 92]. However, two independent reports have suggested detectable amounts of 
zika viremia in whole blood for up to 2 months [93], and 81 days [94] after the onset of 
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symptoms suggesting whole blood can be an ideal body fluid for diagnosis as well as long-
term viral load monitoring in zika positive patients. Additionally, none of the previously 
published literature on LAMP-based zika diagnostics has answered the critical concern of 
multiplexing multiple closely related viruses on a single platform.  
Herein, we report an integrated, lab-on-a-chip method for detection of zika virus in 
spiked whole human blood employing complete hands-free sample processing, a unique 
RT-LAMP assay, and smartphone imaging. Our assay is highly quantitative and can detect 
down to 10 plaque forming units (PFU)/rxn which corresponds to 1.56 × 105 PFU/mL of 
zika virus starting concentration in infected blood in under 35 minutes with minimal sample 
processing. To further extend the clinical significance of our work, we multiplex the 
detection of zika virus with other closely related viral RNAs, dengue-1, dengue-3, and 
chikungunya, on a single microchip. We demonstrate the only platform to date that can 
multiplex detection of viral and other nucleic acid targets on a portable point-of-care setup 
starting from whole blood samples. 
 
3.2. Materials and methods 
3.2.1. Whole zika virus samples 
Whole zika virus (ZIKV) particles (PRVABC59 and MR-766 strains) were 
purchased from BEI Resources (Manassas, VA). The stock vial was aliquoted and stored 
at -80°C. Appropriate stock volumes were used either for direct experimentation with the 
viruses or for RNA extraction. For experiments using whole viruses directly, the 
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appropriate stock volume of the virus was taken and diluted to the right concentrations 
either in whole blood or lysed blood. The whole venous blood samples were drawn from 
healthy, consenting, ZIKV-negative adult volunteers with a syringe, and were later 
transferred to 4 mL BD Vacutainer K2 EDTA collection tubes. The tubes were stored in a 
sample rotisserie at room temperature before using them for experiments. 
ZIKV RNA was purified from whole ZIKV particles using RNeasy Mini Kit 
(Qiagen, Hilden, Germany). Dengue-1, Dengue-3, and Chikungunya virus RNA was 
obtained from BEI resources. The purified RNA was aliquoted and stored at -80 °C until 
used for experiments. Dilution of RNA was usually done in water unless stated otherwise. 
The stock viral RNA was diluted in either DEPC water or whole blood depending on the 
experiments. 
 
3.2.2. Cell lysis buffer 
Blood lysis buffers were prepared in accordance with the work of Curtis et al. [88, 
89], and consisted of 2.5 mM KHCO3, 37.5 mM NH4Cl, and 0.025 mM EDTA. For all 
experiments involving lysed blood, a 1:4 ratio of blood to lysis buffer was used. A manual 
pipettor was used to gauge and mix blood with lysis buffer for all off-chip experiments on 
a benchtop thermocycler. For microfluidic on-chip RT-LAMP experiments with whole 
virus particles/viral RNA in blood, lysis buffer and blood were mixed using a microfluidic 
on-chip pre-processing module which is explained in the section below. The flow ratio for 
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the blood and lysis buffer into the pre-processing microfluidic chip was set to 1:4, using 
two syringe pumps.    
 
3.2.3. Primer sequences 
All primer sequences for the RT-LAMP and RT-PCR reactions were synthesized 
by Integrated DNA Technology and are listed in Table 3.1. PrimerExplorer V4 
(https://primerexplorer.jp/e/) was used for designing the RT-LAMP primers for ZIKV 
RNA. The sequence for zika virus strain MR 766 was obtained from NCBI database using 
NCBI Reference Sequence:  AY632535.2. 
(https://www.ncbi.nlm.nih.gov/nuccore/AY632535?%3Fdb=nucleotide)  and for zika 
virus strain PRVABC59 was obtained from NCBI database using NCBI Reference 
Sequence:  KU501215.1 (https://www.ncbi.nlm.nih.gov/nuccore/KU501215). 
 
3.2.4. Reaction components 
All RT-LAMP assays comprised of the following components: 1X final 
concentration of the isothermal amplification buffer (New England Biolabs), 1.4 mM each 
of deoxy-ribonucleoside triphosphates (dNTPs), 10 mM of MgSO4 (New England Biolabs), 
and 0.4 mol/L of Betaine (Sigma-Aldrich). These components were prepared in bulk and 
stored at –20 °C between experiments. In addition to the buffer components, 3 μL of primer 
mix consisting of 0.2 μM of F3 and B3, 1.6 μM FIP and BIP, and 0.8 μM of LoopF and 
LoopB, 0.64 U/μL Bst 2.0 WarmStart DNA Polymerase (New England Biolabs), 0.08 
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U/μL AMV reverse transcriptase (New England Biolabs), and 1X EvaGreen (Biotium), a 
dsDNA intercalating dye, was included in the reaction. An 8 μL template of the appropriate 
concentration and 0.05 μL of DEPC-treated water (Invitrogen) was added to make the final 
reaction volume 25 μL.  
The RT-PCR reaction was carried with iTaq™ Universal One-Step RT-qPCR Kit 
(Bio-Rad Technologies, ON L5T 1C9, Canada). Briefly, a 20 µL final reaction mix 
contained 10 µL of 2X iTaq universal probes reaction mix, 0.5 µL of iScript advanced 
reverse transcriptase, 2 µL of 0.4 µM forward primer, 2 µL of 0.4 µM reverse primer, 2.8 
µL of 0.2 µM probe, and 2.7 µL of template RNA.  
The templates for the ZIKV RT-LAMP characterization consisted of either purified 
RNA in water, or whole virus particles spiked in whole blood. Ten-fold serial dilutions of 
the templates in appropriate buffer were amplified to determine the working range of our 
developed assays. The RT-PCR reactions were performed with purified RNA in water. For 
the multiplexing tests, the templates for dengue-1, dengue-3, and chikungunya virus 
consisted of the corresponding viral RNA spiked in whole blood, and the ZIKV template 
consisted of whole zika virus spiked in whole blood. The off-chip co-infection test included 
an amalgam of purified viral RNA in water such that the final concentration of each target 
was 1000 PFU/rxn. All the off-chip and on-chip RT-LAMP and RT-PCR reactions 
consisted of non-template negative controls that were included in all the datasets. These 
non-template negative controls on-chip were prepared off-chip and injected into the 
appropriate lanes manually using a syringe. Additionally, the on-chip tests also included 
no primer negative controls to check for any cross-talk between adjacent wells.  
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3.2.5. Reaction platforms 
All the off-chip LAMP tests were carried out in 0.2 mL PCR reaction tubes in the 
RT-PCR System (Eppendorf). The tubes were incubated at 65 °C for 50 minutes in the 
thermocycler, and fluorescent data was recorded every 1 minute. The off-chip PCR tests 
were conducted on the same thermocycler but with the following recipe: RT incubation at 
50 °C for 10 minutes, 3 minutes of DNA denaturation at 95 °C, and 45 cycles of 
thermocycling from 95 °C (15 seconds) to 60 °C (60 seconds). Fluorescence data was 
recorded after each cycle of the reaction. All the on-chip experiments were carried out on 
a silicon biochip using our integrated point-of-care imaging and heating setup as described 
below. 
 
3.2.6. Pre-processing module 
The microfluidic preprocessing module was adapted from the work of Watkins et 
al. [95]. Polydimethylsiloxane (PDMS) was synthesized and poured over a SU-8 master 
mold fabricated using standard cleanroom photolithography techniques. The PDMS was 
then degassed in a vacuum desiccator and incubated in a 60 °C oven for 2-3 hours to cure. 
Cured PDMS block of thickness approximately 5 mm was then cut out from the mold and 
cleaned with isopropyl alcohol (IPA) followed by drying with dry nitrogen to remove any 
impurities from the microfluidic channels. Three inlet holes and one outlet hole were 
drilled into the PDMS using a 0.5 mm needle, for tubing connections. Afterwards, the 
surfaces of the processed PDMS and a clean glass slide were activated using an oxygen 
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plasma system (Pico; Diener, Ebhausen, Germany). Immediately following this, PDMS 
and glass slide were covalently bonded to each other over a hot plate at 120 °C to form the 
complete sample pre-processing module. 
The sample processing module consisted of three inlet ports for three different 
solutions: whole ZIKV or other viral RNA spiked whole blood, RT-LAMP reagents, and 
lysis buffer. The flow rates were controlled using syringe pumps, and were fixed at 1 
µL/min, 3 µL/min, and 10.62 µL/min for virus/RNA in whole blood, lysis buffer, and RT-
LAMP reagents respectively. This setup was kept in the biosafety cabinet, and biosafety 
level 2 protocols were followed during these experiments.  
 
3.2.7. Amplification chip fabrication 
The oxidized silicon chip is roughly the size of a quarter (29 × 29 mm2) and has 6 
interconnected channels at the center and 2 separate, independent channels along the 
periphery. Flow channel dimensions are 10 mm in length, 500 µm in width, and 200 µm in 
depth, representing a volume of 1 µL per channel. The inlet of the chip is a 2 mm diameter 
circle. The fabrication process is described in section 2.2.1. 
 
3.2.8. Chip assembly and sealing 
All the microfluidic chips for on-chip RT-LAMP experiments were cleaned in the 
following steps: First, the chip was cleaned in a Piranha solution containing 1:3 of 30% 
hydrogen peroxide and 98% sulfuric acid for 10 minutes followed by extensive rinsing 
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with DI water to remove any acidic residues. Then, the chip was dried using nitrogen gas 
and immersed in Sigmacote (Sigma-Aldrich) in a sterile petri dish for approximately 5 
minutes to make the surface of the chip and its channels hydrophobic. This is done to 
prevent any non-specific adsorption of biomolecules on the chip surface during the RT-
LAMP reactions. The chip was then rinsed with IPA before being blow-dried with nitrogen 
gas. Chips were placed in sterile glass petri dishes until use.  
Primers were printed on the positive and non-template negative reaction channels 
followed by a short incubation period at room temperature to dry the primers. Briefly, 1X 
concentration of the primer was diluted in 1:3 ratio in DEPC-treated water. Then two drops 
of 0.24 µL of primers were pipetted using a 0.5-10 µL pipette along the center of the 
positive reaction lanes equidistant from each other. Afterwards, DSA membranes 
(Adhesives Research), each with 11 laser-cut holes, attached to three small PDMS blocks 
with holes drilled by a 0.5 mm needle were aligned and attached to the microfluidic silicon 
chips. PDMS blocks were aligned with three inlet ports on the chip: a central inlet port for 
sample injection and two peripheral inlet ports for injection of non-template negative 
controls.  
For experiments with viral nucleic acids in water, the template and the RT-LAMP 
reagents were mixed off-chip, and then injected into the chip using a syringe pump. Once 
the sample was loaded into the chip, the outer layer of the DSA which contained the PDMS 
blocks was peeled off, and the chip was sealed with a second DSA layer to prevent 
evaporation during RT-LAMP incubation. The chip was placed on a credit card sized 
cartridge (85.6 × 54.0 × 0.8 mm3), and the cartridge containing the amplification chip was 
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inserted into our portable point-of-care setup for RT-LAMP reaction, and real-time 
monitoring. The cartridge had an opening where the chip rested which ensured good 
contact with the heater throughout the LAMP incubation step.  
For any experiments involving blood, the pre-processing chip and the amplification 
chip were assembled together on the cartridge, as shown in Figure 3.1. A tube from the 
outlet of the pre-processing chip connected the sample injection port of the amplification 
chip ensuring rapid, reliable, and automated mixing and sample loading into the 
amplification chip. The amplification chip was visually observed for filling, and the 
connecting tube was manually disconnected once filling was complete. The chip was sealed 
in the same procedure as described above. The cartridge containing both the pre-
preprocessing chip and the amplification chip was inserted into the cradle. The 
amplification chip rested atop the heater inside the cradle while pre-processing chip stuck 
out.  
 
3.2.9. Fluorescence imaging system 
The optical imaging system used to excite and detect fluorescent emission from the 
LAMP assay is depicted in Figure 3.1 and 3.2. The system is similar to the instrument that 
was used in Chapter 2 except that the light source module is powered and operated by an 
Arduino Gemma, which is an open-source electronics platform composed of a 
programmable circuit board and control software. The Arduino microcontroller board is 
powered by a lithium-ion battery (3.7 V) and provides 3.3V output by a built-in voltage 
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regulator that powers all eight LEDs consistently. The preprogrammed Arduino board 
regulates the duty cycle and operation frequency of the LED On-Off switching during a 
measurement. For experiments with viral RNA in water, the LED “on” time was 6.1 
seconds, and the “off” time was 53.9 seconds, and for experiments of RNA/whole virus 
particles in whole blood, the LED “on” time was set to 10 seconds, and the “off” time was 
set to be 50 seconds. The card that contains the amplification chip is inserted into the cradle 
such that it is in contact with the PTC heater that allows the chip temperature to stabilize 
near 65 ˚C. The PTC heater is powered by a battery set (10.5 V) composed of two standard 
9 V batteries and two 1.5 V AA batteries each to set the temperature of the microfluidic 
chip around 64 ~ 66 ˚C for 60 minutes to perform one LAMP assay (Figure 3.3). The LEDs 
and the heater are turned on and off by two separate toggle switches. The transmitted 
fluorescent light through the macro lens and long pass filter is captured using the 
smartphone rear-facing camera in an 8-bit 3-channel JPG image format.  
 
3.2.10. Image processing 
There was a need for a remote-controlled imaging function in the smartphone 
because the assays needed to be conducted in a biosafety cabinet due to safety 
considerations. IP Webcam [96] is an Android application that allows the user to transmit 
live images over a wireless network, which can be subsequently observed in real time in a 
web browser. IP Webcam was downloaded from the Google Play Store and installed on 
the smartphone. The remote browser control allowed regulation of the smartphone 
camera’s zoom, exposure, gain, stream quality and imaging/video recording capabilities. 
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Two different sets of parameters were used for imaging of viral nucleic acids in water and 
whole virus particles/RNA in whole blood. The following parameters were used in IP 
Webcam for imaging of RT-LAMP on-chip reactions using viral nucleic acids: 1.42 X 
zoom, 99% stream quality, and night vision function with a gain of 10X and an exposure 
of 3. For imaging of RT-LAMP reactions using whole virus particles/viral nucleic acids in 
spiked in whole blood, the following parameters were used: 1.42X zoom, 99% stream 
quality, and night vision function with a gain of 15X and an exposure of 10. 
Images recorded with IP Webcam in the smartphone were saved in TIFF format 
from which fluorescence intensity was analyzed in an automated fashion using a MATLAB 
script. Grayscale images were first imported as an array of 8-bit unsigned integers (range 
0-255), which represented each pixel in the image. Then, the average fluorescence 
intensities from only the channel portions of the chip were extracted using a polygonal 
virtual mask. Such time-lapsed fluorescence values for each channel were obtained from 
the time-lapsed images and a fluorescence vs. time curve was plotted. The baseline (initial) 
fluorescence value was subtracted for each curve to account for the differences in starting 
fluorescence values per channel.  
All on-chip and off-data RT-LAMP and RT-PCR data was analyzed and plotted 
using a MATLAB script. For all the off-chip and on-chip experiments, the threshold time 
was taken as the time taken for an amplification curve to reach 20% of its maximum 
intensity. For on-chip reactions, the fluorescent intensity on-chip was extracted from each 
channel and was plotted against time to generate the raw fluorescence curves. Each raw 
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amplification curve was fitted to a sigmoidal curve using a four-point parameter modeling 
(Figure 3.4). The following equation was used for the analysis:  
𝑓 = 𝑦0 +  
𝑎
1 +  𝑒−(
𝑥−𝑥0
𝑏 )
 
where f = fluorescence intensity, 𝑦0 = background fluorescence at time = 0 minutes, 𝑎 = 
difference between the initial and final fluorescent intensity, x = time point of analysis, 𝑥0 
= inflection point of the curve, b = slope of the curve. The threshold time was obtained at 
the point where the fluorescent intensity = 𝑦0 + 0.2𝑎. The positive and negative wells were 
differentiated on the basis of the R2 value of the sigmoidal fit and the parameters  𝑎  and  
𝑥0 . The threshold time was taken as the point of inflection. Negative wells had a 
combination of low R2 value, low 𝑎 value, or a very high threshold time (𝑥0 > 50 minutes). 
 
3.3. Results and discussion 
Figure 3.1 shows the process flow of the on-chip multiplexed pathogen detection 
from a finger prick of whole blood sample. The point-of-care diagnostics and monitoring 
platform can be divided into three primary modules: A, B and C. Module A is the PDMS 
microfluidic sample processing chip where infected whole blood is first lysed and then 
mixed with amplification reagents. This chip has 3 inlets ports for infected blood, lysing 
buffer and RT-LAMP amplification reagents respectively, and 1 outlet port for 
amplification-ready processed analyte. The robustness of RT-LAMP reaction to inhibitors 
allows for replacing the usual RNA purification steps required before amplification 
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reactions with simple sample lysis and the on-chip sample processing module A translates 
the routine manual pipetting steps to a complete hands-off platform. Next, the processed 
sample from Module A is transferred to Module B, which is the oxidized silicon chip with 
six microfluidic channels, for isothermal amplification. RT-LAMP primers specific to 
different pathogens are pre-dried in different channels of the chip as a part of chip 
preparation. After the processed sample is transferred into these channels, the chip is sealed 
with the DSA to prevent sample evaporation during incubation. As shown in Figure 3.1, 
the modules A and B are incorporated in a “diagnostics card” which is similar to a credit 
card in appearance and this card can be customized according to the pathogens to be 
detected or quantified in the patient blood by pre-printing the specific primers. Module C 
is the point-of-care setup comprising the smartphone, the PTC heater, and the 
optomechanical components for real-time fluorescence imaging. Once the “diagnostics 
card” and the smartphone are in place, the heater and LED are turned on and real-time 
fluorescence imaging of the on-chip RT-LAMP reaction is performed using the smartphone. 
Only the channel with primers specific to the pathogen in patient blood sample lights up 
over time whereas the fluorescence for the other channels remains at an initial baseline 
level. Amplification curves are generated with this real-time fluorescence data and 
threshold times for amplification are obtained. These threshold times can then be mapped 
to a standard curve database for the pathogen and the exact concentration of the pathogen 
in patient blood sample can also be obtained. This quantitative capability of the platform 
becomes crucial in scenarios where changes in pathogen concentration in patient samples 
need to be monitored over time, such as for viral load monitoring in response to retroviral 
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therapy in HIV patients, and in dengue virus infections where high viremia presentation 
has been linked to secondary infection and disease severity. 
 
3.3.1. Characterization of RT-LAMP in a benchtop thermocycler 
The ZIKV PRVABC59 was isolated from the blood of a human in Puerto Rico in 
December 2015 [97]. NS1 gene in ZIKV has previously been used for specifically detecting 
ZIKV using RT-PCR assay [98]. Figure 3.5 shows the off-chip characterization of the RT-
LAMP assay in the benchtop thermocycler apparatus. Figure 3.5(a,b) show the baseline-
subtracted change in fluorescent intensity over time for different concentrations of ZIKV 
RNA, and the corresponding threshold time against the PFU equivalent of purified RNA 
per reaction. We observed a good linear fit for the standard curve (R2 = 0.9755) and a lower 
LOD of 10 PFU equivalent of purified RNA per reaction (reaction volume = 25 µL) 
corresponding to 1250 PFU/mL purified RNA in starting concentration. To compare the 
ZIKV RT-LAMP reaction with the previously published CDC RT-PCR assay for ZIKV 
[99], we carried out RT-PCR experiments with same ZIKV RNA concentrations as used 
for RT-LAMP using the CDC RT-PCR primers and obtained the amplification and 
standard curves. Figure 3.5(c,d) show the baseline-subtracted change in fluorescent 
intensity over time for different concentrations and the corresponding standard curve for 
the RT-PCR assay, respectively. The lower LOD for the RT-PCR assay was found to be 1 
PFU equivalent of purified RNA per reaction (20 µL) corresponding to 370 PFU/mL 
purified RNA in starting concentration. A similar novel RT-LAMP reaction was designed 
and characterized for the MR 766 Uganda strain of the ZIKV (Genbank: AY632535.2) and 
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compared to CDC RT-PCR assay as shown in Figure 3.6 and 3.7. A good linear fit was 
observed for the standard curve (R2 = 0.9755), and the lower LOD was determined to be 
10 PFU equivalent of purified RNA per reaction which corresponded 1250 PFU/mL 
purified RNA starting concentration.  
As a next step, to characterize the feasibility of the RT-LAMP reaction from 
minimally processed samples, different concentrations of whole zika viruses were spiked 
in lysed whole blood and the reactions were performed in the thermocycler. Figure 3.5(e,f) 
show the baseline-subtracted change in fluorescent intensity over time for different 
concentrations of viruses and the corresponding threshold time against whole ZIKV PFU 
per reaction. Similar to the RT-LAMP reaction with purified RNA, ZIKV spiked in lysed 
whole blood showed a good linear fit for the standard curve (R2 = 0.9047) and a lower LOD 
of 10 PFU per reaction in 25 µL tube based reactions. This corresponded to a starting ZIKV 
sample concentration of 6250 PFU/mL in blood. We observed reduced fluorescence 
intensity in RT-LAMP reactions with lysed whole blood which is consistent with previous 
reports [82]. These results show that our RT-LAMP reaction is robust to the debris present 
in lysed whole blood and serves as a proof-of-concept for the on-chip reactions from 
processed whole blood. 
To perform multiplexed pathogen detection on the same chip, we selected two other 
closely related viruses, dengue virus (DENV; strain 1 and 3) and chikungunya virus 
(CHIKV), to multiplex with ZIKV on the chip. Since ZIKV infection shares symptoms 
with other febrile diseases such as dengue and chikungunya, accurate diagnosis is required 
to differentiate these infections during the acute phase of the disease. As RT-LAMP 
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reactions for these pathogens already existed in literature [100-102], we used these 
previously published primers (Table 3.1) and validated them in a tube-based thermocycler 
reaction. Figure 3.8 shows the amplification curves for DENV-1, DENV-3, and CHIKV 
RNA in water as a test of previously published primers. Figure 3.9 shows the amplification 
curves for the RT-LAMP reactions from DENV-1, DENV-3, CHIKV, and ZIKV RNA 
spiked in lysed whole blood against different primer sets. As summarized in Table 3.2, 
only the specific template-primer pairs amplify in each of the panels validating the usability 
of these primer sets in multiplexing experiments. We also demonstrate the specificity of 
the ZIKV assay in the rare case of co-infection where multiple pathogens might be present 
simultaneously in the patient blood sample. As shown in Figure 3.10, we demonstrate in a 
tube-based thermocycler reaction that our assay can specifically detect ZIKV in the 
presence of DENV-1, DENV-3, and CHIKV simultaneously in a single reaction. 
 
3.3.2. Microfluidic chip based sample processing 
The next step towards a complete point-of-care system was to process the infected 
blood sample on-chip to make it suitable for amplification. In a two-step process, the 
infected whole blood was first mixed with lysing buffer and then with amplification 
reagents in the PDMS microfluidic chip. Figure 3.11 shows the complete process flow and 
the chip layout. Independent characterization of this microfluidic sample processing 
module was done to compare its performance with routine manual pipetting/mixing based 
methods and to assess its potential for automation and integration with the point-of-care 
setup. 10 µL of whole blood sample spiked with 625 PFU/μL ZIKV was metered and 
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injected into the PDMS microfluidic chip concurrently with lysis buffer and RT-LAMP 
reagents through the labelled inlets. The output was collected from this microfluidic chip 
on four separate instances and RT-LAMP experiments on each instance were performed 
on the thermocycler. As a control, four replicates of the same ZIKV spiked whole blood 
sample were mixed with lysis buffer and RT-LAMP reagents manually using a pipette and 
analyzed in a thermocycler. Figure 3.11(a) shows the amplification curve for the two 
mixing scenarios, and Figure 3.11(b) shows the corresponding threshold time bar graphs. 
The threshold times for on-chip and manual sample processing technique were found to be 
very similar to the deviation in the on-chip processing threshold time, being 3.6% from off-
chip processing threshold time. The on-chip mixing was also confirmed visually by 
observing different regions of the chip during the processing step. Figure 3.11(c) shows 
the bright-field microscopy images of these regions. 
 
3.3.3. Characterization of ZIKV RT-LAMP assay 
After the characterization of the RT-LAMP reactions in the thermocycler, we 
translated and characterized these reactions on the microfluidic chip and performed them 
on the point-of-care setup developed. RT-LAMP reactions with purified ZIKV RNA in 
water and ZIKV spiked in whole blood were performed on the chip with ten-fold serial 
dilutions, and the working range and LOD of the assays were determined. The integrated 
heater in the setup maintained a temperature of 64-66°C, which was appropriate for the 
reactions to take place. Figure 3.3 shows the results for our point-of-care setup heater 
characterization. Real-time images were captured by smartphone, and threshold time 
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analysis was performed using a MATLAB script. For both sets of experiments, 3 
alternating channels (in the primary hexagon shape) on the microchip, and 2 separate non-
template negative control channels on the chip periphery were printed with ZIKV primers. 
The remaining 3 channels are left unprinted to serve as on-chip no-primer controls which 
are simultaneously performed in each experimental run. Thus the chip in total has 3 positive 
reaction channels, 3 negative no-primer control channels, and 2 negative no-template 
control channels as shown in the chip layout (Figure 3.12). Together they ensure that the 
amplification results obtained are from specific ZIKV reactions only and not from spurious, 
non-specific amplification.    
For the on-chip RT-LAMP characterization with purified RNA, template (purified 
RNA in water) and the RT-LAMP reagents without primers were mixed manually using a 
pipette, and 7 µL of the final reaction mix was injected into the amplification chip (module 
B) using a syringe pump. The chip was sealed to prevent evaporation and contamination, 
and the diagnostics card consisting of the amplification chip was inserted into the cradle. 
Figure 3.12(a) shows the time-lapsed fluorescence images of a representative RT-LAMP 
reaction on-chip showing the amplification of only positive channels. The images shown 
are for RT-LAMP reaction from 10 PFU equivalent of purified RNA per reaction. Figure 
3.12(b-d) show the raw amplification curves, the amplification curves after sigmoidal 
fitting, and the threshold-time standard curves for these reactions. We observe a lower LOD 
of purified RNA equivalent to 10 PFU per reaction (1 channel = 1 reaction = 1 µL) 
corresponding to 3.125 × 104 PFU/mL in starting concentration. A good linear fit was 
observed in the standard curve (R2 = 0.99) with distinct threshold times per ten-fold change 
in template concentration.        
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The complete diagnostics card with the sample processing chip (module A) 
connected to the amplification chip (module B) was used to characterize the RT-LAMP 
reactions with ZIKV in whole blood. The ZIKV infected blood sample was first processed 
in module A and then allowed to flow directly into the amplification chip. Upon filling, the 
chip was sealed, and the diagnostics card was inserted into the cradle. The cradle design 
allows the amplification chip to sit on top of the heater while the sample processing module 
sticks out. Figure 3.12 (e-g) show the raw amplification curves, the amplification curves 
after sigmoidal fitting, and the threshold-time standard curves for these reactions. A good 
linear fit was observed in the standard curve (R2 = 0.9913) with ZIKV detection down to 
10 copies per µL of final reaction (1 channel = 1 reaction = 1 uL) corresponding to 1.56× 
105 PFU/mL starting virus concentration. With clinically significant LOD from infected 
blood samples, the results of this experiment demonstrated that our on-chip assay can 
successfully monitor viral loads via RT-LAMP reactions with hands-free sample 
processing, a portable cradle setup, and smartphone-based imaging that can be easily 
translated for use at the point-of-care. 
 
3.3.4. Multiplexed pathogen detection on a microfluidic chip 
The platform was put to the final test of analyzing samples containing different 
pathogens on the diagnostics card. ZIKV, DENV-1, DENV-3, and CHIKV primers were 
simultaneously printed in different channels on our amplification chip (module B) per the 
pattern. The complete integrated setup was used for these experiments to demonstrate their 
efficacy in a clinical setting. The chips were challenged with either 1.56×104 PFU/µL of 
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whole ZIKV in starting blood sample or 1.56×104 copies/µL of purified RNA of either 
DENV-1, DENV-3, or CHIKV in starting blood sample, and separate point-of-care RT-
LAMP experiments were performed. Figure 3.13 shows the multiplexed detection of ZIKV, 
DENV-1, DENV-3, and CHIKV from whole blood respectively. In each of the case, we 
observe that only the lanes with specific template-primer set amplify while the remaining 
lanes remain at baseline fluorescence during the entire reaction. These reactions 
demonstrate the capability of our platform to specifically diagnose and provide clinically 
actionable information for different pathogens at the point-of-care from infected whole 
blood samples.  
The viral load of ZIKV in serum has been reported to be 1×103 - 1×106 PFU/mL 
[103]. Although the exact viral load in whole blood in the acute infection stage has never 
been reported, we can estimate this by using the threshold cycle published by Murray et al. 
[94], and our own standard curve for the same qRT-PCR reactions (CDC assay). We 
estimate that the viral load in whole blood based on that report would be on the order of 1× 
106 PFU/mL or higher during the acute phase of infection (threshold time ~22 cycles from 
Murray et al.). Moreover, a recent review article [104] stresses the need for point-of-care 
zika diagnostic platforms with limits of detection in the picomolar range from biofluids, 
which translates to 6×108 particles per mL. Since our point-of-care on-chip assay can detect 
as low as 1.56×105 PFU/mL from infected whole blood sample it lies within the clinically 
significant range of zika viremia. Although no direct correlation has been found between 
the viremia in blood and the clinical presentations, higher viremia has been indicative of 
more severe infection resulting in hospitalization (on average 107copies/mL), and in one 
case higher viremia in blood has resulted in the direct transmission of the infection due to 
 87 
 
close contact with the patient (~108 copies/mL). This presents the need for accurate 
quantification of the viremia especially at the onset of the disease when the viral load in 
blood is high. Moreover, the viral loads in all biological samples have been reported to 
decline significantly after the onset of symptoms, making early diagnosis vital. Our 
portable, smartphone-based setup can be easily adapted to test patient samples at the point-
of-care leading to early and accurate disease diagnosis. The low reagent consumption on-
chip and the ability to test for multiple pathogens on the same pre-printed microfluidic chip 
greatly reduces the cost per test and allows diagnosis from a simple finger prick. The 
process can be further simplified for use in point-of-care settings by freeze-drying the RT-
LAMP reagents beforehand and rehydrating them in buffer solutions prior to loading in the 
sample processing chip. 
 
3.4. Conclusion 
Our battery-powered cradle with an embedded optical detection system and 
integrated heater, coupled with smartphone imaging, provides a portable and easy-to-use 
platform that greatly reduces instrument costs. The smartphone gives real-time visual 
output of the test which is fed directly into an external computer, reducing handling with 
potential infectious materials. The use of smartphone as the detector allows the possibility 
to develop applications that can automate the data analysis process, allow personalized 
patient care, and build databases for epidemiological surveillance. As a proof of concept, 
we have multiplexed the detection of four different targets on a single chip from the same 
starting material in a single reaction. Although we have detected one target at a time, our 
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device can also detect multiple pathogens simultaneously as in the case of co-infections. 
Our device offers great design flexibility as the number of lanes can be increased to 
incorporate the detection of more targets, and different primer sequences can be printed on 
the lanes depending on demographic prevalence of the infections. 
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3.5. Figures 
 
Figure 3.1. Schematic and POC process flow of the ZCD Viral Detection system. (1) 
Patient sample from a finger prick of blood is collected and loaded into the pre-processing 
module. (2) Automated on-chip mixing of the sample with the lysis buffer and RT-LAMP 
reagents takes place within minutes in sample processing module (module A). (3) The 
complete reaction mix is loaded onto the amplification chip (module B). (4) The 
amplification module is completely sealed and Viral Diagnostics Card is inserted into the 
cradle. (5) The smartphone is positioned on top of the cradle and focused to image the 
entire chip. The heating switch is turned on to incubate the amplification chip for the RT-
LAMP reaction. The silicon amplification chip sits atop the heating element and is in 
contact with the heater during the entire RT-LAMP incubation process. (6) The LED switch 
is turned on for sample illumination. (7) Real-time fluorescence imaging of the 
amplification reaction is performed using the smartphone and the results of the RT-LAMP 
reaction are visually displayed on the smartphone screen. The lighting up of a channel 
indicated the presence of the corresponding pathogen in the patient blood.  
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Figure 3.2. Microfluidic chip and cradle setup. (a) Image of the integrated chips (before 
experiment) in a credit card sized holder (left). Image of a filled and completely sealed chip 
after the pre-processing steps (top right), and image of the smartphone cradle setup imaging 
the chip (bottom right). The credit card-sized holder can be inserted into the cradle such 
that the amplification chip sits on the heater and the pre-processing chip sticks out. The 
holder can be readily removed after the experiment. (b) Cross-section of the smartphone 
cradle setup showing the inner components and circuitry. 
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Figure 3.3. Cradle Heater Characterization. Temporal temperature gradients measured 
from five different points on the microfluidic chip. The temperature reaches at 65 ˚C in 5 
minutes after the heater beneath the chip is turned on and is kept above 65 ˚C over 65 
minutes. Inset shows the temperature gradients of the points marked on the chip for 60 
minutes to perform one LAMP assay. Each point represents an average value from three 
independent measurements, and the error bars represent three standard deviations.    
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Figure 3.4. Sigmoidal fitting of raw amplification curves. Sigmoidal fitting on 
representative data from a positive and negative channel using the 4-point parameter model 
described in methods section. The threshold time was taken as the time when 20% of 
maximum intensity is reached in the sigmoidal fit.  
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Figure 3.5. Thermocycler-based ZIKV RT-LAMP reaction characterization. (a-b) 
Baseline-subtracted raw amplification curves showing the change in fluorescence over 
time and the calculated standard curve of the RT-LAMP assay for ZIKV PRVABC59 
purified RNA. (c-d) Baseline-subtracted raw amplification curves showing the change in 
fluorescence over time and the standard curve of the RT-PCR assay for ZIKV PRVABC59 
purified RNA. (e-f) Baseline-subtracted raw amplification curves showing the change in 
fluorescence over time and the standard curve of the RT-LAMP assay for whole ZIKV 
PRVABC59 spiked in lysed whole blood. The results demonstrate the range and lower LOD 
of our assay in thermocycler-based reactions from purified ZIKV RNA and whole ZIKV 
in lysed whole blood. 
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Figure 3.6. Off-chip RT-LAMP characterization of ZIKV MR-766 strain. Baseline-
subtracted raw amplification curves showing the changes in fluorescence over time and the 
calculated threshold-time curve of the RT-LAMP assay designed to detect ZIKV MR-766 
purified RNA. This primer set was specific to the MR-766 strain only and not to the 
PRVABC59 strain. The same was the case for the primer sets detecting the PRVABC59 
strain.  
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Figure 3.7. Off-chip RT-PCR characterization of ZIKV MR-766 strain. Baseline-
subtracted raw amplification curves showing the changes in fluorescence over time and the 
standard threshold-time curve of the CDC RT-PCR assay designed to detect ZIKV MR-
766 purified RNA. 
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Figure 3.8. Off-chip RT-LAMP assay validation. Baseline-subtracted raw amplification 
curves showing the changes in fluorescence over time for different template-primer set 
pairs to validate and determine the working primer sets for future experiments. A second 
validation experiment was carried out by spiking the RNA of the above flaviruses in lysed 
and carrying out RT-LAMP reaction.  
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Figure 3.9. Off-chip multiplexing of four viral targets. Baseline-subtracted raw 
amplification curves showing the changes in fluorescence over time in separate RT-LAMP 
reactions to detect (a) ZIKA virus, (b) Dengue-1 virus, (c) Dengue-3 virus, and (d) 
Chikungunya virus templates. All the templates were challenged with all the primer sets 
and the result demonstrates that only the correct template-primer pair amplifies. The 
template in figures a-c contains 1000 copies/rxn (25 µL) of Dengue-1,3 and Chikungunya 
purified RNA spiked in lysed whole blood. The template in figure d contains 1000 PFU/rxn 
(25 µL) of whole ZIKV spiked in lysed whole blood. 
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Figure 3.10. Co-infection test. Baseline-subtracted RT-LAMP raw amplification curves 
showing the changes in fluorescence over time to detect purified ZIKV RNA in the 
presence of closely related contaminating RNA. Three different scenarios of ZIKV 
infections were tested: 1. ZIKV with contaminating RNA, 2. ZIKV without contaminating 
RNA, and 3. Contaminant without the ZIKV RNA. The first two cases yielded 
amplification and similar threshold times, whereas the final scenario yielded no 
amplification, confirming the specificity of our designed primer to ZIKV even in the 
presence of multiple contaminating RNA. The contaminants included a mixture of DENV-
1, DENV-3 and CHIKV purified RNA, all at the concentration of 1000 copies per reaction. 
ZIKV purified RNA concentration was 1000 PFU equivalent of RNA per reaction. 
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Figure 3.11. Microfluidic sample processing characterization. (a) Baseline-subtracted 
raw amplification curves showing the changes in fluorescence over time for on-chip and 
off-chip sample processing (blood lysis and reagent mixing) using whole blood sample 
containing 625 PFU/µL ZIKV. (b) Threshold-time bar graphs comparing the on-chip and 
off-chip sample processing. The final product of the microfluidic mixing was pipetted into 
tubes and thermocycler-based RT-LAMP reactions were performed. Control thermocycler- 
based RT-LAMP reactions with same ZIKV in blood concentrations were performed after 
sample processing through manual pipetting. (c) Images showing mixing of the blood-lysis 
buffer- amplification reagents at different points in the channels of the pre-processing chip.  
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Figure 3.12. On-chip RT-LAMP assay characterization. (a) Raw fluorescence images 
of the amplification chip at time = 0, 14, 28, and 42 minutes respectively showing the 
amplification of only positive channels for RT-LAMP reaction with purified RNA. The 
images shown are for 10 PFU equivalent of purified RNA/µL of ZIKV in final reaction.  
(b) Raw amplification curves of the ZIKV RT-LAMP assay on-chip carried out from 
purified RNA, and (c) the same amplification curves after sigmoidal fitting. (d) The 
standard curve of the ZIKV RT-LAMP assay with purified RNA. A LOD of 3.125×104 
PFU/mL equivalent of purified RNA/mL in starting sample of ZIKV RNA in water was 
observed. (e) Raw amplification curve of the ZIKV RT-LAMP assay on-chip carried out 
with whole viruses in whole blood and (f) the same amplification curves after sigmoidal 
fitting. (g) The standard curve of the ZIKV RT-LAMP assay with virus in whole blood. A 
LOD of 1.56× 105 PFU/mL of ZIKV in starting infected blood sample was observed. All 
experiments involving blood were carried out using the integrated setup.  
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Figure 3.13. On-chip multiplexing of four viral targets. Raw fluorescence images of the 
amplification chip at t = 0, 14, and 28 minutes respectively and raw amplification curves 
of the RT-LAMP reaction showing multiplexed detection of viral RNAs of (a) zika, (b) 
dengue-1, (c) dengue-3, and (d) chikungunya from infected whole blood samples in four 
separate experiments using the same chip layout with pre-printed primers. Primers for each 
of these pathogens were simultaneously printed in different channels of the chip and this 
layout was kept constant across the different on-chip multiplexing experiments. The 
starting concentration of ZIKV and the other viral RNAs in blood was equal to 1.56×104 
PFU/mL or copies/µL in starting blood sample. 
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3.6. Tables 
Table 3.1. Sequence of primers used in the LAMP assays 
 
 
  
PRVABC59 NS1 
RT-LAMP primers 
F3: GAC CCC ATC AAC GTG GTG 
B3: CCA CAC TCT TTC CTG AGA CC 
FIP: TCA GGC CAA CAG CTG TGA GTA CGA CTG CTG TTG CTC ACA 
AGG 
BIP: CGC ATT GGC TGG AGG GTT CGT GAC AAT TAG CAG ACC 
GAC C 
Loop F: CAG CTC CGC TTC CCA CT 
Loop B: AGG CAG ATA TAG AGA TGG CTG G 
MR-766 
RT-LAMP primers 
F3: TTC GTG GAG GGC ATG TCA 
B3: GAC TGT CCG AAG CCA TGT C 
FIP: CCT GTG CCA TCA CGG TAA CGC GGT GGG ACC TGG GTT GAT 
BIP: TAG AGT TGG TCA CGA CGA CGG TCG ATA TCG ATG CCT CGT 
AGC 
Loop F: AGC CTC CAT GTT CCA AGA CAA 
Loop B: AAC ATG GCC GAG GTA AGA TCC 
Dengue-1 
RT-LAMP primers 
F3: TGT GTT CCT CCT TCT CAT AAT G 
B3: CAG ACT CAA TCC AAT CGT AAG A 
FIP: CAT CCT GTC TGA AGC ATT GGC TGG ACA ATT GAC ATG GAA 
TGA TC 
BIP: CCT AGC TCT GAT GGC CAC TTT CTT CTC TAG ATG TTA GTC 
TGC G 
Loop F: CCA ACC ATG ATG CAT AAC CTG 
Loop B: ATG AGA CCA ATG TTC GCT GT 
Dengue-3 
RT-LAMP primers 
F3: CCC GTC CAA GGA CGT TAA 
B3: CTG CTG CGT TGT GTC ATG 
FIP: CG ACG GAG CTA CAG GCA GAA GAA GTC AGG CCC AAA 
BIP: GGG ACG TAA AGC CTG GGA GCC TCT AAC CAC TAG 
TCT GCT A 
Loop F: GTT TGC TCA AAC CGT GGC 
Loop B: AAC CGT GGA AGC TGT ACG 
Chikungunya 
RT-LAMP primers 
F3: ACG CAA TTG AGC GAA GCA C 
B3: CTG AAG ACA TTG GCC CCA C 
FIP: CGG ATG CGG TAT GAG CCC TGT ATG GAG AAG TCC 
GAA TCA TGC 
BIP: TCC GCG TCC TTT ACC AAG GAA ATT TGG CGT CCT 
TAA CTG TGA C 
Loop F: GCT GAT GCA AAT TCT GT 
Loop B: CCT ATG CAA ACG GCG AC 
Zika Envelope 
RT-PCR primers 
Forward: CCG CTG CCC AAC ACA AG 
Reverse: CCA CTA ACG TTC TTT TGC AGA CAT 
Probe: /56-FAM/AGC CTA CCT /ZEN/TGA CAA GCA GTC AGA 
CAC TCA A/3IABkFQ/ 
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Table 3.2. Summary of all template-primer tests 
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CHAPTER 4 
CONCLUSION 
 
The development of personalized medical service or point-of-care diagnostics has 
been a long-cherished desire of humankind, and there is tremendous interest in a 
generational shift of bio/chemical diagnosis using mobile platforms that would enable 
disease diagnostics, pathogen detection, and chemical analysis to be performed in point-
of-use scenarios. Since the introduction of smartphones, hundreds of millions of the 
devices have been sold, with competition among platforms resulting in ever-increasing 
capabilities for computation, display, and wireless connectivity. Especially smartphone 
cameras developed for producing high-resolution images and operating under low-light 
conditions have proven sufficient to detect light emitters utilized for various bio/chemical 
assays [25, 27, 28, 30, 57, 61, 62, 65-71, 82]. In each of the studies, the smartphone camera 
was used as a sensor to perform functions comparable to much larger and more expensive 
laboratory instruments.  
In this work, we advanced the previous researches of the smartphone-based sensor 
and first demonstrated the use of mobile platform technology for performing detection of 
the genus flavivirus and equine pathogens using the loop-mediated isothermal 
amplification and identification of the counterfeit medications using thin layer 
chromatography. In particular, the system we developed communicated results to a cloud-
based data management system along with other relevant information provided by the user, 
and it would facilitate global surveillance networks and monitoring. In the smartphone-
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based LAMP assays, a portable and affordable cradle that interfaces with a smartphone, 
holds internal optomechanical components, and provides a dark environment was 
developed to measure the fluorescence that emerged as a result of amplification of the 
nucleic acids of interest conducted on the microfluidic chip/plate. The use of a macro lens, 
an integrated light module, optical filters, and a PTC heater permitted the development of 
the low-cost and handheld cradle, while adoption of the microfluidic chip approach using 
LAMP enabled the fast, accurate, and multiplexed diagnosis of diseases at the point-of-
care. Furthermore, the automated real-time measurement was achieved by the battery-
powered Arduino board. We also developed a smartphone-based instrument with TLC 
assay to distinguish the counterfeit from the genuine. By integrating the handheld UV lamp, 
the system functioned as a portable scanner to analyze TLC plate analysis for identification 
of falsified and substandard medications. The portable TLC plate reading platform 
integrated with a smartphone enabled direct visualization of principal spots on the plate 
and provided spot intensity and travel distance of each spot to verify quality and identity 
of the API. For both bio and chemical sensing approaches, customized app or external 
computing system were used to process the digital image captured and share the results 
through a cloud-based center.  
We have implemented the generational shift of the bio/chemical sensing techniques. 
We developed the smartphone-based systems and demonstrated the operation of the 
instruments by the analysis of viral and bacterial pathogens and medications.  Not only did 
the systems show comparable sensing capabilities in comparison with conventional 
laboratory equipment, but they expanded the functions by adopting cloud-based data 
management to achieve global monitoring and networks. These POC systems would 
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provide versatile approaches for fast, affordable, and accurate diagnosis and be utilized as 
powerful tools for more accessible healthcare, especially for people in low-income and 
resource-limited regions. 
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